

Third National Health and Nutrition Examination Survey
(NHANES III), 1988-94

NHANES III PARTIAL HOUSEHOLD ADULT DATA FILE DOCUMENTATION
(VITAMIN, MINERAL, AND MEDICINE USAGE - SECTION X ONLY)

Series 11, No. 2A

April 1998

*Special Note:

(Response to vitamin, mineral & prescription questions)

These files contain the responses to the vitamin/mineral supplement and prescription medicine questions from the Household Adult and Youth questionnaires, respectively. In addition, "Adultx" also contains the antacid and non-prescription pain relief medicine questions from the Household Adult questionnaire. Responses for each of these four questions are listed as one record per respondent. These files do not contain the dietary supplement or prescription medicine product codes. One must use the respondent identification number (SEQN) to link the records in this file with most other files. This file cannot be directly linked to the dietary supplements concentration database files. These files contain overview discussions about the prescription medicine, antacid, and non-prescription medicines sections of the questionnaire as well as specific notes on selected variables.

Table of Contents

Introduction	
Guidelines for Data Users.	
Survey Description	
Sample Design and Analysis Guidelines.	
Data Preparation and Processing Procedures	
General References	
NHANES III Household Adult Data File (Vitamin, Mineral, and Medicine Usage)	
General Information	
Data File Index	
Data File Item Descriptions, Codes, Counts, and Notes	
Appendices	

Introduction

The National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates data on the health status of U.S. residents. The results of surveys, analyses, and studies are made known through a number of data release mechanisms including publications, mainframe computer data files, CD-ROMs (Search and Retrieval Software, Statistical Export and Tabulation System (SETS)), and the Internet.

The National Health and Nutrition Examination Survey (NHANES) is a periodic survey conducted by NCHS. The third National Health and Nutrition Examination Survey (NHANES III), conducted from 1988 through 1994, was the seventh in a series of these surveys based on a complex, multi-stage sample plan. It was designed to provide national estimates of the health and nutritional status of the United States' civilian, noninstitutionalized population aged two months and older.

The following table summarizes the NHANES III data which are currently available on CD-ROM, including this release.

Table 1. Available NHANES III CD-ROMs

CD-ROM Name	Release Date	Size in Megabytes	Data Files / Description
NHANES III, 1988-94, Series 11, No. 2A, ASCII Version (this release)	April 1998	407	Dietary recall (replacement), electrocardiography, laboratory (additional analytes), and vitamins/medicines data files and documentation
NHANES III, 1988-94, Series 11, No. 1, Revised SETS Version 1.22a	October 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation, plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias
NHANES III, 1988-94, Series 11, No. 1A, ASCII Version	July 1997	454	Adult and youth household questionnaire, dietary recall, examination, and laboratory data files and documentation
NHANES III, 1988-94, Series 11, No. 1, SETS Version 1.22a *	July 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation
NHANES III Reference Manuals and Reports October 1996	October 1996	152	Plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias

* Do not use this CD-ROM It had technical problems and has been

superseded by the revised SETS version 1.22a, Series 11, No. 1, released in October 1997.

This release, Series 11, No. 2A, contains previously unreleased data and corrections. Corrections were made to the vitamin/minerals portion of the adult and youth questionnaire data files as well as the dietary recall portion of the examination data file. For the laboratory component, some previously release variables have been augmented with NHANES III Phase 2 data. In addition several new laboratory variables have been added.

The following table shows which public use files contain information from the interview and examination components.

Table 2. Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Sample weights	X	X	X	X	.	.	X
Age/race/sex	X	X	X	X	.	.	X
Ethnic background	X	X
Household composition	X	X
Individual characteristics	X	X
Health insurance	X	X
Family background	X	X
Occupation of family head	X	X
Housing characteristics	X	X
Family characteristics	X	X
Orientation	X	X
Health services	X	X
Selected health conditions	X	X	X
Diabetes questions	X
High blood pressure and cholesterol questions	X
Cardiovascular disease questions	X
Musculoskeletal conditions	X
Physical functioning questions	X
Gallbladder disease questions	X

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

	Data File						
Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Kidney conditions	X
Respiratory and allergy questions	X	X
Diet questions	X
Food frequency	X	.	X
Vision questions	X	X
Hearing questions	X	X
Dental care and status	X	X
Tobacco	X	.	X
Occupation	X
Language usage	X	X
Exercise	X
Social support/residence	X
Vitamin/mineral/medicine usage	X	X	X
Blood pressure measurement	X	.	X
Birth	.	X	X
Infant feeding practices/diet	.	X
Motor and social development	.	X
Functional impairment	X	X
School attendance	.	X
Cognitive function	.	X	X

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Alcohol and drug use	.	.	X
Reproductive health	.	.	X
Diagnostic interview schedule	.	.	X
Activity	.	.	X
Physician's examination	.	.	X
Height and weight	.	.	X
Body measurements	.	.	X
Dental examination	.	.	X
Allergy skin test	.	.	X
Audiometry	.	.	X
Tympanometry	.	.	X
WISC and WRAT	.	.	X
Spirometry	.	.	X
Bone densitometry	.	.	X
Gallbladder ultrasonography	.	.	X
Central nervous system function evaluation	.	.	X
Fundus photography	.	.	X
Physical function evaluation	.	.	X
Fasting questions	.	.	.	X	.	.	.

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Topic	Data File							
	HA	HY	EXAM	LAB	DIET	VMS	ECG	
Laboratory tests on blood and urine	.	.	.	X	.	.	.	
Total nutrient intakes	.	.	X	
Individual foods	X	.	.	
Combination foods	X	.	.	
Ingredients	X	.	.	
Prescription Medicines	X	X	.	.	.	X	.	
Vitamins and Minerals	X	X	.	.	.	X	.	
Electrocardiography	X	

Data File Definitions

- HA - Household Adult Data File
- HY - Household Youth Data File
- EXAM - Examination Data File
- LAB - Laboratory Data File and Second Laboratory Data File
- DIET - Dietary Recall Data Files
- VMS - Vitamin Mineral Supplement Data File
- ECG - Electrocardiography Data File

This document includes the documentation for the NHANES III Partial Household Adult Data File Documentation (vitamin, mineral, and medicine usage - section X only) and also contains a general overview of the survey and the use of the data files. The general overview includes five sections. The first section, entitled "Guidelines for Data Users," contains important information about the use of the data files. The second section, "Survey Description," is a brief overview of the survey plan and operation. The third section, "Sample Design and Analysis Guidelines," describes some technical aspects of the sampling plan and discusses some analytic issues particularly related to the use of data from complex sample surveys. The "Data Preparation and Processing Procedures" section describes the editing conventions and the codes used to represent the data. The last and fifth section, "General References," includes a reference list for the survey overview sections of the document.

Public Use Data Files for the third National Health and Nutrition Examination Survey will also be available from the National Technical Information Service (NTIS). A list of NCHS public use data tapes available for purchase from NTIS may be obtained from the Data Dissemination Branch at NCHS. Information regarding a bibliography (on disk) of journal articles citing data from all the NHANES and the availability of NHANES III data in CD-ROM/SETS software format can be obtained from the Data Dissemination Branch at:

Data Dissemination Branch
National Center for Health Statistics
Room 1018
6525 Belcrest Road
Hyattsville, Maryland 20782

Phone: (301)436-8500

URL:<http://www.cdc.gov/nchswww>

NTIS can be contacted at:

NTIS - Computer Products Office
5285 Port Royal Road
Springfield, Virginia 22161
(703) 487-4807

Copies of all NHANES III questionnaires and data collection forms are included in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996). This publication, along with detailed information on NHANES procedures, interviewing, data collection, quality control techniques, survey design, nonresponse, and sample weighting can be found on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996). Information on how to order this CD-ROM is also available from the Data Dissemination Branch at NCHS at the address and telephone number given above.

GUIDELINES FOR DATA USERS

Please refer to the following important information before analyzing data.

NHANES III Background Documents

- o The Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94, (NCHS, 1994; U.S. DHHS, 1996) provides an overview of the survey and includes copies of the survey forms.
- o The sample design, nonresponse, and analytic guidelines documents on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) discuss the reasons that sample weights and the complex survey design should be taken into account when conducting any analysis.
- o Instruction manuals, laboratory procedures, and other NHANES III reference manuals on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) are also available for further information on the details of the survey.

Analytic Data Set Preparation

- o Most NHANES III survey design and demographic variables are found only on the Adult and Youth Household Data Files available on the first release. In preparing a data set for analysis, other data files must be merged with either or both of these files to obtain many important analytic variables.
- o All of the NHANES III public use data files are linked with the common survey participant identification number (SEQN). Merging information from multiple NHANES III data files using this variable ensures that the appropriate information for each survey participant is linked correctly.
- o NHANES III public use data files do not have the same number of records on each file. The Household Questionnaire Files (divided into two files, Adult and Youth) contain more records than the Examination Data File because not everyone who was interviewed completed the examination. The Laboratory Data File contains data only for persons aged one year and older. The Individual Foods Data File based on the dietary recall has multiple records for each person rather than the one record per sample person contained in the other data files.
- o For each data file, SAS program code with standard variable names and labels is provided as separate text files on the CD-ROM that contains the data files. This SAS program code can be used to create a SAS data set from the data file.
- o Modifications were made to items in the questionnaires, laboratory, and examination components over the course of the survey; as a result, data may not be available for certain variables for the full six years. In addition, variables may differ by phase since some changes were implemented between phases. Users are encouraged to read the Notes

sections of this document carefully for information about changes.

- o Extremely high and low values have been verified whenever possible, and numerous consistency checks have been performed. Nonetheless, users should examine the range and frequency of values before analyzing data.
- o Some data were not ready for release at the time of this publication due to continued processing of the data or analysis of laboratory specimens. A listing of those data are available in the general information section of each data file.
- o Confidential and administrative data are not being released to the public. Additionally, some variables have been recoded to help protect the confidentiality of the survey participants. For example, all age-related variables were recoded to 90+ years for persons who were 90 years of age and older.
- o Some variable names may differ from those used in the Phase 1 NHANES III Provisional Data Release and some variables included in the Phase 1 provisional release may not appear on these files.
- o Although the data files have been edited carefully, errors may be detected. Please notify NCHS staff (301-436-8500) of any errors in the data file or the documentation.

Analytic Considerations

- o NHANES III (1988-94) was designed so that the survey's first three years, 1988-91, its last three years, 1991-94, and the entire six years were national probability samples. Analysts are encouraged to use all six years of survey results.
- o Sample weights are available for analyzing NHANES III data. One of the following three sample weights will be appropriate for nearly all analyses: interviewed sample final weight (WTPFQX6), examined sample final weight (WTPFEX6), and mobile examination center (MEC)- and home-examined sample final weight (WTPFHX6). Choosing which of these sample weights to use in any analysis depends on the variables being used. A good rule of thumb is to use "the least common denominator" approach. In this approach, the user checks the variables of interest. The variable that was collected on the smallest number of persons is the "least common denominator," and the sample weight that applies to that variable is the appropriate one to use for that analysis. For more detailed information, see the Analytic and Reporting Guidelines for NHANES III (U.S. DHHS, 1996).

Referencing or Citing NHANES III Data

- o In publications, please acknowledge NCHS as the original data source. For instance, the reference for the NHANES III Laboratory Data File On this CD-ROM is:

U.S. Department of Health and Human Services (DHHS). National Center

for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Second Laboratory Data File (CD-ROM, Series 11, No. 2A). Hyattsville, MD.: Centers for Disease Control and Prevention, 1998.

- o Please place the acronym "NHANES III" in the titles or abstracts of journal articles and other publications in order to facilitate the retrieval of such materials in bibliographic searches.

SURVEY DESCRIPTION

The third National Health and Nutrition Examination Survey (NHANES III) was the seventh in a series of large health examination surveys conducted in the United States beginning in 1960. Three of these surveys, the National Health Examination Surveys (NHES), were conducted in the 1960's (NCHS, 1965; NCHS, 1967; NCHS, 1969). In 1970, an expanded nutrition component was added to provide data with which to assess nutritional status and dietary practices, and the name was changed to the National Health and Nutrition Examination Survey (Miller, 1973; Engel, 1978; McDowell, 1981). A special survey of Hispanic populations in the United States was conducted during 1982-1984 (NCHS, 1985).

The general structure of the NHANES III sample design was similar to that of the previous NHANES. All of the surveys used complex, multi-stage, stratified, clustered samples of civilian, noninstitutionalized populations. NHANES III was the first NHANES without an upper age limit; in fact, the age range for the survey was two months and older. A home examination option was employed for the first time in order to obtain examination data for very young children and for elderly persons who were unable to visit the mobile examination center (MEC). The home examination included only a subset of the components used in the full MEC examination since it would have been difficult to collect some types of data in a home setting. A detailed description of design specifications and copies of the data collection forms can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996).

NHANES III was conducted from October 1988 through October 1994 in two phases, each of which comprised a national probability sample. The first phase was conducted from October 18, 1988, through October 24, 1991, at 44 locations. The second phase was conducted from September 20, 1991, through October 15, 1994, at 45 different locations. In NHANES III, 39,695 persons were selected over the six years; of those, 33,994 (86%) were interviewed in their homes. All interviewed persons were invited to the MEC for a medical examination. Seventy-eight percent (30,818) of the selected persons were examined in the MEC, and an additional 493 persons were given a special, limited examination in their homes.

Data collection began with a household interview. Several questionnaires were administered in the household: Household Screener Questionnaire, Family Questionnaire, Household Adult Questionnaire, and Household Youth Questionnaire.

At the MEC, an examination was performed, and five automated questionnaires or interviews were administered: MEC Adult Questionnaire, MEC Youth Questionnaire, MEC Proxy Questionnaire, 24-Hour Dietary Recall, and Dietary Food Frequency (ages 12-16 years). The health examination component included a variety of tests and procedures. The examinee's age at the time of the interview and other factors determined which procedures were administered. Blood and urine specimens were obtained, and a number of tests and measurements were performed including body measurements, spirometry, fundus photography, x-rays, electrocardiography, allergy and glucose tolerance tests, and ultrasonography. Measurements were taken of bone density, hearing, and physical, cognitive, and central nervous system

functions. A physician performed a limited standardized medical examination and a dentist performed a standardized dental examination. While some of the blood and urine analyses were performed in the MEC laboratory, most analyses were conducted elsewhere by contract laboratories.

A home examination was conducted for those sample persons aged 2-11 months and aged 20 years or older who were unable to visit the mobile examination center. The home examination consisted of an abbreviated version of the tests and interviews performed in the MEC. Depending on age of the sample person, the components included body measurements, blood pressure, spirometry, venipuncture, physical function evaluation, and a questionnaire to inquire about infant feeding, selected health conditions, cognitive function, tobacco use, and reproductive history.

SAMPLE DESIGN AND ANALYSIS GUIDELINES

Sample Design

The general structure of the NHANES III sample design is the same as that of the previous NHANES. Each of these surveys used a stratified, multi-stage probability design. The major design parameters of the two previous NHANES and the special Hispanic HANES, as well as NHANES III, have been previously summarized (Miller, 1973; McDowell, 1981; NCHS, 1985; NCHS, 1994). The NHANES III sample was designed to be self-weighting within a primary sampling unit (PSU) for subdomains (age, sex, and race-ethnic groups). While the sample was fairly close to self-weighting nationally for each of these subdomain groups, it was not representative of the total population, which includes institutionalized, non-civilian persons that were outside the scope of the survey.

The NHANES III sample represented the total civilian, noninstitutionalized population, two months of age or over, in the 50 states and the District of Columbia of the United States. The first stage of the design consisted of selecting a sample of 81 PSU's that were mostly individual counties. In a few cases, adjacent counties were combined to keep PSU's above a minimum population size. The PSU's were stratified and selected with probability proportional to size (PPS). Thirteen large counties (strata) were chosen with certainty (probability of one). For operational reasons, these 13 certainty PSU's were divided into 21 survey locations. After the 13 certainty strata were designated, the remaining PSU's in the United States were grouped into 34 strata, and two PSU's were selected per stratum (68 survey locations). The selection was done with PPS and without replacement. The NHANES III sample therefore consists of 81 PSU's or 89 locations.

The 89 locations were randomly divided into two groups, one for each phase. The first group consisted of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased estimates (from the point of view of sample selection) of health and nutrition characteristics can be independently produced for both Phase 1 and Phase 2 as well as for both phases combined.

For most of the sample, the second stage of the design consisted of area segments composed of city or suburban blocks, combinations of blocks, or other area segments in places where block statistics were not produced in the 1980 Census. In the first phase of NHANES III, the area segments were used only for a sample of persons who lived in housing units built before 1980. For units built in 1980 and later, the second stage consisted of sets of addresses selected from building permits issued in 1980 or later. These are referred to as "new construction segments." In the second phase, 1990 Census data and maps were used to define the area segments. Because the second phase followed within a few years of the 1990 Census, new construction did not account for a significant part of the sample, and the entire sample came from the area segments.

The third stage of sample selection consisted of households and certain types of group quarters, such as dormitories. All households and eligible group quarters in the sample segments were listed, and a subsample was designated for screening to identify potential sample persons. The

subsampling rates enabled production of a national, approximately equal-probability sample of households in most of the United States with higher rates for the geographic strata with high Mexican-American populations. Within each geographic stratum, there was a nearly equal-probability sample of households across all 89 stands.

Persons within the sample of households or group quarters were the fourth stage of sample selection. All eligible members within a household were listed, and a subsample of individuals was selected based on sex, age, and race or ethnicity. The definitions of the sex, age, race or ethnic classes, subsampling rates, and designation of potential sample persons within screened households were developed to provide approximately self-weighting samples for each subdomain within geographic strata and at the same time to maximize the average number of sample persons per sample household. Previous NHANES indicated that this increased the overall participation rate. Although the exact sample sizes were not known until data collection was completed, estimates were made. Below is a summary of the sample sizes for the full six-year NHANES III at each stage of selection:

Number of PSU's	81
Number of stands (survey locations)	89
Number of segments	2,144
Number of households screened	93,653
Number of households with sample persons	19,528
Number of designated sample persons	39,695
Number of interviewed sample persons	33,994
Number of MEC-examined sample persons	30,818
Number of home-examined sample persons	493

More detailed information on the sample design and weighting and estimation procedures for NHANES III can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996) and in the Analytic and Reporting Guidelines: Third National Health and Nutrition Examination Survey (NHANES III), 1988-94 (U.S. DHHS, 1996).

Analysis Guidelines

Because of the complex survey design used in NHANES III, traditional methods of statistical analysis based on the assumption of a simple random sample are not applicable. Detailed descriptions of this issue and possible analytic methods for analyzing NHANES data have been described earlier (NCHS, 1985; Yetley, 1987; Landis, 1982; Delgado, 1990). Recent analytic and reporting guidelines that should be used for most NHANES III analyses and publications are contained in Analytic and Reporting Guidelines (U.S. DHHS, 1996). These recommendations differ slightly from those used by analysts for previous NHANES surveys. These suggested guidelines provide a framework to users for producing estimates that conform to the analytic design of the survey. All users are strongly urged to review these analytic and reporting guidelines before beginning any analyses of NHANES III data.

It is important to remember that this set of statistical guidelines is not absolute. When conducting analyses, the analyst needs to use his/her subject matter knowledge (including methodological issues) as well as information about the survey design. The more one deviates from the original

analytic categories defined in the sample design, the more important it is to evaluate the results carefully and to interpret the findings cautiously.

In NHANES III, 89 survey locations were randomly divided into two sets or phases, the first consisting of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased national estimates of health and nutrition characteristics can be independently produced for each phase as well as for both phases combined. Computation of national estimates from both phases combined (i.e., total NHANES III) is the preferred option; individual phase estimates may be highly variable. In addition, individual phase estimates are not statistically independent. It is also difficult to evaluate whether differences in individual phase estimates are real or due to methodological differences. That is, differences may be due to changes in sampling methods or data collection methodology over time. At this time, there is no valid statistical test for examining differences between Phase 1 and Phase 2. Therefore, although point estimates can be produced separately for each phase, no test is available to test whether those estimates are significantly different from each other.

NHANES III is based on a complex, multi-stage probability sample design. Several aspects of the NHANES design must be taken into account in data analysis, including the sample weights and the complex survey design. Appropriate sample weights are needed to estimate prevalence, means, medians, and other statistics. Sample weights are used to produce correct population estimates because each sample person does not have the same probability of selection. The sample weights incorporate the differential probabilities of selection and include adjustments for noncoverage and nonresponse. A detailed discussion of nonresponse adjustments and issues related to survey coverage have been published (U.S. DHHS, 1996). With the large oversampling of young children, older persons, black persons, and Mexican-Americans in NHANES III, it is essential that the sample weights be used in all analyses. Otherwise, a misinterpretation of results is highly likely. Other aspects of the design that must be taken into account in data analyses are the strata and PSU pairings from the sample design. These pairings should be used to estimate variances and test for statistical significance. For weighted analyses, analysts can use special computer software packages that use an appropriate method for estimating variances for complex samples such as SUDAAN (Shah, 1995) and WesVarPC (Westat, 1996).

Although initial exploratory analyses may be performed on unweighted data using standard statistical packages and assuming simple random sampling, final analyses should be done on weighted data using appropriate sample weights. A summary of the weighting methodology and the type of sample weights developed for NHANES III is included in Weighting and Estimation Methodology (U.S. DHHS, 1996).

The purpose of weighting the sample data is to permit analysts to produce estimates of statistics that would have been obtained if the entire sampling frame (the United States) had been surveyed. Sample weights can be considered as measures of the number of persons the particular sample observation represents. Weighting takes into account several features of the survey: the specific probabilities of selection for the individual domains that were oversampled as well as nonresponse and differences between the sample and the total U.S. population. Differences between the sample and the population may arise due to sampling variability, differential

undercoverage in the survey among demographic groups, and possibly other types of response errors, such as differential response rates or misclassification errors. Sample weighting in NHANES III was used to:

1. Compensate for differential probabilities of selection among subgroups (i.e., age-sex-race-ethnicity subdomains where persons living in different geographic strata were sampled at different rates);
2. Reduce biases arising from the fact that nonrespondents may be different from those who participate;
3. Bring sample data up to the dimensions of the target population totals;
4. Compensate, to the extent possible, for inadequacies in the sampling frame (resulting from omissions of some housing units in the listing of area segments, omissions of persons with no fixed address, etc.); and
5. To reduce variances in the estimation procedure by using auxiliary information that is known with a high degree of accuracy.

In NHANES III, the sample weighting was carried out in three stages. The first stage involved the computation of weights to compensate for unequal probabilities of selection (objective 1, above). The second stage adjusted for nonresponse (objective 2). The third stage used poststratification of the sample weights to Census Bureau estimates of the U.S. population to accomplish the third, fourth, and fifth objectives simultaneously. In NHANES III, several types of sample weights (see the sample weights table that follows) were computed for the interviewed and examined sample and are included in the NHANES III data file. Also, sample weights were computed separately for Phase 1 (1988-91), Phase 2 (1991-94), and total NHANES III (1988-94) to facilitate analysis of items collected only in Phase 1, only in Phase 2, and over six years of the survey. Three sets of pseudo strata and PSU pairings are provided to use with SUDAAN in variance estimation. Since NHANES III is based on a complex, multi-stage sample design, appropriate sample weights should be used in analyses to produce national estimates of prevalence and associated variances while accounting for unequal probability of selection of sample persons. For example, the final interview weight, WTPFQX6, should be used for analysis of the items or questions from the family or household questionnaires, and the final MEC examination weight, WTPFEX6, should be used for analysis of the questionnaires and measurements administered in the MEC. Furthermore, for a combined analysis of measurements from the MEC examinations and associated medical history questions from the household interview, the final MEC examination weight, WTPFEX6, should be used. We recommend using SUDAAN (Shah, 1995) to estimate statistics of interest and the associated variance. However, one can also use other published methods for variance estimation. Application of SUDAAN and alternative methods, such as the average design effect approach, balance repeated replication (BRR) methods, or jackknife methods for variance estimation, are discussed in Weighting and Estimation Methodology (U.S. DHHS, 1996).

Appropriate Uses of the NHANES III Sample Weights

Final interview weight, WTPFQX6

Use only in conjunction with the sample interviewed at home and with items collected during the household interview.

Final examination (MEC only) weight, WTPFEX6

Use only in conjunction with the MEC-examined sample and with interview and examination items collected at the MEC.

Final MEC+home examination weight, WTPFHX6

Use only in conjunction with the MEC+home-examined sample and with items collected at both the MEC and home.

Final allergy weight, WTPFALG6

Use only in conjunction with the allergy subsample and with items collected as part of the allergy component of the exam.

Final CNS weight, WTPFCNS6

Use only in conjunction with the CNS subsample and with items collected as part of the CNS component of the exam.

Final morning examination (MEC only) subsample weight, WTPFSD6

Use only in conjunction with the MEC-examined persons assigned to the morning subsample and only with items collected in the MEC exam.

Final afternoon/evening examination (MEC only) subsample weight, WTPFMD6

Use only in conjunction with the MEC-examined persons assigned to the afternoon/evening subsample and only with items collected in the MEC exam.

Final morning examination (MEC+home) subsample weight, WTPFHSD6

Use only in conjunction with the MEC- and home-examined persons assigned to the morning subsample and with items collected during the MEC and home examinations.

Final afternoon/evening examination (MEC+home) weight, WTPFHMD6

Use only in conjunction with the MEC- and home-examined persons assigned to the afternoon/evening subsample and with items collected during the MEC and home examinations.

DATA PREPARATION AND PROCESSING PROCEDURES

Automated data collection procedures for the survey were introduced in NHANES III. In the mobile examination centers, data for the interview and examination components were recorded directly onto a computerized data collection form. With the exception of a few independently automated systems, the system was centrally integrated. This operation allowed for ongoing monitoring of much of the data. Before the introduction of the computer-assisted personal interview (CAPI), the household questionnaire data were reviewed manually by field editors and interviewers. CAPI (1992-1994 only) questionnaires featured built-in edits to prevent entering inconsistencies and out-of-range responses. The multi-level data collection and quality control systems are discussed in detail in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996). All interview, laboratory, and examination data were sent to NCHS for final processing.

Guidelines were developed that provided standards for naming variables, filling missing values and coding conventional responses, handling missing records, and standardizing two-part quantity/unit questionnaire variables. NCHS staff, assisted by contract staff, developed data editing specifications that checked data sets for valid codes, ranges, and skip pattern consistencies and examined the consistency of values between interrelated variables. Comments, collected in both interviews and examination components, were reviewed and recoded when possible. Responses to "Other" and "Specify" were recoded either to existing code categories or to new categories. The documentation for each data set includes notes for those variables that have been recoded and standardized and for those variables that differ significantly from what appears in the original data collection instrument. While the data have undergone many quality control and editing procedures, there still may be values that appear extreme or illogical. Values that varied considerably from what was expected were examined by analysts who checked for comments or other responses that might help to clarify unusual values. Generally, values were retained unless they could not possibly be true, in which case they were changed to "Blank but applicable." Therefore, the user must review each data set for extreme or inconsistent values and determine the status of each value for analysis.

Several editing conventions were used in the creation of final analytic data sets:

1. Standardized variables were created to replace all two-part quantity/unit questions using standard conversion factors. Standardized variables have the same name as the variable of the two-part question with an "S" suffix. For instance, MAPF18S (Months received WIC benefits) in the MEC Adult Questionnaire was created from the two-part response option to question F18, "How long did you receive benefits from the WIC program?," using the conversion factor 12 months per year.
2. Recoded variables were created by combining responses from two or more like variables, or by collapsing responses to create a summary variable for the purpose of confidentiality. Recoded variables have the original variable name with an R suffix. For example, place of birth

variable (HFA6X) in the Family Questionnaire was collapsed to a three level response category (U.S., Mexico, Other) and renamed HFA6XR. Generally, only the recoded variable has been included in the data file.

3. Fill values, a series of one or more digits, were used to represent certain specific conditions or responses. Below is a list of the fill values that were employed. Some of the fill values pertain only to questionnaire data, although 8-fill and blank-fill values are found in all data sets. Other fill values, not included in this list, are used to represent component-specific conditions.

6-fills = Varies/varied. (Questionnaires only)

7-fills = Fewer than the smallest number that could be reported within the question structure (e.g., fewer than one cigarette per day). (Questionnaires only)

8-fills = Blank but applicable/cannot be determined. This means that a respondent was eligible to receive the question, test, or component but did not because of refusal, lack of time, lack of staff, loss of data, broken vial, language barrier, unreliability, or other similar reasons.

9-fills = Don't know. This fill was used only when a respondent did not know the response to a question and said, "I don't know." (Questionnaires only)

Blank fills = Inapplicable. If a respondent was not eligible for a questionnaire, test, or component because of age, gender, or specific reason, the variable was blank-filled. In the questionnaire, if a respondent was not asked a question because of a skip-pattern, variables corresponding to the question were blank-filled. For examination or laboratory components, if a person was excluded by a defined protocol (e.g., screening exclusion questions) and these criteria are included in the data set, then the corresponding variables were blank-filled for that person. For home examinees, variables for examination components and blood tests not performed as part of the home examination protocol were blank-filled.

4. For variables describing discrete data, codes of zero (0) were used to mean "none," "never," or the equivalent. Value labels for which "0" is used include: "has not had," "never regularly," "still taking," or "never stopped using." Unless otherwise labeled, for variables containing continuous data, "zero" means "zero."
5. Where there are logical skip patterns in the flow of the questionnaire or examination component, the skip was indicated by placing the variable label of the skip destination in parentheses as part of the value label of the response generating the skip. For example, in the Physical Function Evaluation, the variable PFPWC (in wheelchair) has a value label, "2 No (PFPSCOOT)" that means that the next item for persons not in a wheelchair would be represented by the variable, PFPSCOOT.

A unique name was assigned to every NHANES III variable using a standard convention. By following this naming convention, the origin of each variable is clear, and there is no chance of overlaying similar variables across multiple components. Variables range in length from three to eight characters. The first two variable characters represent the topic (e.g., analyte, questionnaire instrument, examination component) and are listed below alphabetically by topic. For questionnaires administered in the household, the remainder of the variable name following the first two characters indicates the question section and number. For example, data for the response to the Household Adult Questionnaire question B1 are contained in the variable HAB1. For most laboratory and examination variables, as well as some other variables, a "P" in the third position refers to "primary" and the remainder of the variable name is a brief description of the item. For instance, in the Laboratory Data File, information on the length of time the person fasted before the first blood draw is contained in the variable PHPFAST. The variable PHPFAST was derived as follows: characters 1-2 (PH) refer to "phlebotomy," character 3 (P) refers to "primary," characters 4-8 (FAST) refer to an abbreviation for "fasting."

CODE	TOPIC
AT	Alanine aminotransferase (from biochemistry profile)
AM	Albumin (from biochemistry profile)
AP	Alkaline phosphatase (from biochemistry profile)
AL	Allergy skin test
AC	Alpha carotene
AN	Anisocytosis
TM	Antimicrosomal antibodies
TA	Antithyroglobulin antibodies
AA	Apolipoprotein (AI)
AB	Apolipoprotein (B)
AS	Aspartate aminotransferase (from biochemistry profile)
LA	Atypical lymphocyte
AU	Audiometry
BA	Band
BO	Basophil
BS	Basophilic stippling
BC	Beta carotene
BX	Beta cryptoxanthin
BL	Blast
BU	Blood urea nitrogen (BUN) (from biochemistry profile)
BM	Body measurements
BD	Bone densitometry
C1	C-peptide (first venipuncture)
C2	C-peptide (second venipuncture)
CR	C-reactive protein
CODE	TOPIC
UD	Cadmium
CN	Central nervous system function evaluation
CL	Chloride (from biochemistry profile)
CO	Cotinine
CE	Creatinine (serum)(from biochemistry profile)

UR	Creatinine (urine)
DM	Demographic
DE	Dental examination
MQ	Diagnostic interview schedule
DR	Dietary recall (total nutrient intakes)
EO	Eosinophil
EP	Erythrocyte protoporphyrin
FR	Ferritin
FB	Fibrinogen
RB	Folate (RBC)
FO	Folate (serum)
FH	Follicle stimulating hormone (FSH)
FP	Fundus photography
GG	Gamma glutamyl transferase (GGT) (from biochemistry profile)
GU	Gallbladder ultrasonography
GB	Globulin (from biochemistry profile)
G1	Glucose (first venipuncture)
G2	Glucose (second venipuncture)
SG	Glucose (from biochemistry profile)
GH	Glycated hemoglobin
GR	Granulocyte
C3	HCO ₃ (Bicarbonate)(from biochemistry profile)
HD	HDL cholesterol
HP	Helicobacter pylori antibody
HT	Hematocrit
HG	Hemoglobin
AH	Hepatitis A antibody (HAV)
HB	Hepatitis B core antibody (anti-HBc)
SS	Hepatitis B surface antibody (anti-HBs)
SA	Hepatitis B surface antigen (HBsAg)
HC	Hepatitis C antibody (HCV)
DH	Hepatitis D antibody (HDV)
H1	Herpes 1 antibody
H2	Herpes 2 antibody
HX	Home examination (general)
HO	Homocysteine
HF	Household family questionnaire
HA	Household adult questionnaire
HQ	Household questionnaire variables (composite)
HS	Household screener questionnaire
HY	Household youth questionnaire
HZ	Hypochromia
I1	Insulin (first venipuncture)
I2	Insulin (second venipuncture)
UI	Iodine (urine)
FE	Iron
SF	Iron (from biochemistry profile)
CODE	TOPIC

LD	Lactate dehydrogenase (from biochemistry profile)
L1	Latex antibody
LC	LDL cholesterol (calculated)
PB	Lead
LP	Lipoprotein (a)
LH	Luteinizing hormone
LU	Lutein/zeaxanthin

LY	Lycopene
LM	Lymphocyte
MR	Macrocyte
MC	Mean cell hemoglobin (MCH)
MH	Mean cell hemoglobin concentration (MCHC)
MV	Mean cell volume (MCV)
PV	Mean platelet volume
MA	MEC adult questionnaire
MX	MEC examination (general)
FF	Dietary food frequency (ages 12-16 years)
MP	MEC proxy questionnaire
MY	MEC youth questionnaire
ME	Metamyelocyte
MI	Microcyte
MO	Monocyte
MN	Mononuclear cell
ML	Myelocyte
IC	Normalized calcium (derived from ionized calcium)
OS	Osmolality (from biochemistry profile)
PH	Phlebotomy data collected in MEC (e.g., questions)
PS	Phosphorus (from biochemistry profile)
PF	Physical function evaluation
PE	Physician's examination
PL	Platelet
DW	Platelet distribution width
PK	Poikilocytosis
PO	Polychromatophilia
SK	Potassium (from biochemistry profile)
PR	Promyelocyte
RC	Red blood cell count (RBC)
RW	Red cell distribution width (RDW)
RE	Retinyl esters
RF	Rheumatoid factor antibody
RU	Rubella antibody
WT	Sample weights
SE	Selenium
SI	Sickle cell
NA	Sodium (from biochemistry profile)
SH	Spherocyte
SP	Spirometry
SD	Survey design
TT	Target cell
TE	Tetanus
TH	Thyroid Stimulating Hormone (TSH)
T4	Thyroxine
TB	Total bilirubin (from biochemistry profile)

CODE	TOPIC
------	-------

CA	Total calcium
SC	Total calcium (from biochemistry profile)
TC	Total cholesterol
CH	Total cholesterol (from biochemistry profile)
TI	Total iron binding capacity (TIBC)
TP	Total protein (from biochemistry profile)
TX	Toxic granulation
TO	Toxoplasmosis antibody

PX	Transferrin saturation
TG	Triglycerides
TR	Triglycerides (from biochemistry profile)
TY	Tympanometry
UA	Uric acid (from biochemistry profile)
UB	Urinary albumin
VU	Vacuolated cells
VR	Varicella antibody
VA	Vitamin A
VB	Vitamin B12
VC	Vitamin C
VD	Vitamin D
VE	Vitamin E
WC	White blood cell count (WBC)
WW	WISC/WRAT cognitive test

GENERAL REFERENCES

- Delgado JL, Johnson CL, Roy I, Trevino FM. Hispanic Health and Nutrition Examination Survey: methodological considerations. *Amer J Pub Health* 80(suppl.):6-10. 1990.
- Engel A, Murphy RS, Maurer K, Collins E. Plan and operation of the HANES I Augmentation Survey of Adults 25-74 Years, United States, 1974-75. National Center for Health Statistics. *Vital Health Stat* 1(14). 1978.
- Freeman DH, Freeman JL, Brock DB, Koch GG. Strategies in the multivariate analysis of data from complex surveys II: an application to the United States National Health Interview Survey. *Int Stat Rev* 40(3):317-30. 1976.
- Khare M, Mohadjer LK, Ezzati-Rice TM, Waksberg J. An evaluation of nonresponse bias in NHANES III (1988-91). 1994 Proceedings of the Survey Research Methods section of the American Statistical Association. 1994.
- Landis JR, Lepkowski JM, Eklund SA, Stehouwer SA. A statistical methodology for analyzing data from a complex survey, the first National Health and Nutrition Examination Survey. National Center for Health Statistics. *Vital Health Stat* 2(92). 1982.
- McDowell A, Engel A, Massey JT, Maurer K. Plan and operation of the second National Health and Nutrition Examination Survey, 1976-80. National Center for Health Statistics. *Vital Health Stat* 1(15). 1981.
- Miller HW. Plan and operation of the Health and Nutrition Examination Survey, United States, 1971-1973. National Center for Health Statistics. *Vital Health Stat* 1(10a) and (10b). 1973.
- National Center for Health Statistics. Plan and initial program of the Health Examination Survey. *Vital Health Stat* 1(4). 1965.
- National Center for Health Statistics. Plan and operation of a health examination survey of U.S. youths 12-17 years of age. *Vital Health Stat* 1(8). 1969.
- National Center for Health Statistics. Plan and operation of the Hispanic Health and Nutrition Examination Survey, 1982-84. *Vital Health Stat* 1(19). 1985.
- National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. *Vital Health Stat* 1(32). 1994.
- National Center for Health Statistics. Plan, operation, and response results of a program of children's examinations. *Vital Health Stat* 1(5). 1967.
- Shah BV, Barnwell BG, Bieler GS. SUDAAN User's Manual: Software for Analysis of Correlated Data. Research Triangle Park, NC: Research Triangle Institute. Release 6.04. 1995.
- Skinner CJ. Aggregated analysis: standard errors and significance tests.

In: Skinner CJ, Holt D, Smith TMF, eds. Analysis of complex surveys. New York: John Wiley and Sons, Inc. 1989.

U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. NHANES III reference manuals and reports (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996. Available from National Technical Information Service (NTIS), Springfield, VA. Acrobat .PDF format; includes access software: Adobe Systems, Inc. Acrobat Reader 2.1.

Westat, Inc. A User's Guide to WesVarPC. Rockville, MD. Westat, Inc. 1996.

Yetley E, Johnson C. Nutritional applications of the Health and Nutrition Examination Surveys (HANES). Annu Rev Nutr 7:441-63. 1987.

NHANES III Partial Household Adult Data File Documentation
(Vitamin, Mineral, And Medicine Usage)

General Information

Household Questionnaire: Prescription Medicines

During the household interview, respondents were asked a series of questions about prescription medicines used during the past month. A proxy, usually a child's parent or guardian, provided this information for children 2 months to 16 years of age. If respondents or proxy respondents reported taking a prescription medicine, they were asked the number of prescription medicines they took. For each medication reported, the interviewer asked to see the medication container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Respondents or proxies were also asked to describe the health problem for which they took the medicine, and how long they had been taking the medicine. Analysts should be aware, however, that there were respondents or proxies who reported taking prescription medicines, but did not answer some or all of the remaining questions about the prescription medicines. In other cases respondents or proxies reported a health problem and/or duration they took a medication, but did not know the name of the medication or NCHS staff could not identify the name. In both cases, the missing fields are coded as either "blank but applicable" (8-fill) or "don't know" (9-fill), whichever was applicable.

Some prescription medicines originally reported in the supplements, antacid, or non-prescription drug sections of the questionnaire were moved to the prescription medicine section of the questionnaire. Some prescribed vitamin and/or mineral supplements, originally reported in the prescription medicines section, could be considered both a drug or a supplement (e.g., calciferol, niacin, calcitriol, and potassium). These products were copied to the dietary supplements section.

In general, non-prescription medications that were reported in the prescription drug section of the household adult questionnaire were moved to the non-prescription medications section (the expanded non-prescription pain relief medications section to be described later), but those medications reported on the household youth questionnaire were deleted since a non-prescription medications section was not include on the youth questionnaire. However, for both the household youth and adult questionnaires if a particular medication reported in the prescription medication section of the questionnaire was available in both prescription and non-prescription strengths (e.g., ibuprofen), the staff assumed it was a prescription medication and left it in this section. On the adult questionnaire, aspirin was moved to the non-prescription medications sections unless the strength or brand name reported was only available by prescription (e.g., "Zorprin"). Also on the household adult questionnaire, prescription antacids were left in this section, but over-the-counter antacids were moved to the antacid section unless, at the time of the survey, the antacid was only available by prescription (e.g., "Zantac").

Each prescription medicine name reported in the survey was located in the Physicians' GenRx, and assigned the standard generic name and 4-digit generic code for that product. However, for five prescription medications a generic name or code did not exist. The NCHS staff created product codes for these medicines. See the notes associated with this variable in the data file layout for a detailed discussion of the prescription medication product code. A list of the standardized generic prescription medication names and their associated

product codes can be found in Appendix 1.

In some cases it may appear as though respondents reported the same prescription medicine more than once. That is, the same generic prescription medicine name and product code may be listed more than once. There are a number of reasons for these duplications. Respondents may have reported different brand name medicines which had the same generic name (e.g., "Adalat" vs. "Procardia"), or the medicines may have been different forms (e.g., tablet vs. patch), strengths (e.g., 20 mg vs. 30 mg), or dosages (e.g., once a day vs. twice a day) of the same product. Based on the information collected when respondents reported different brand names of the same generic product it was difficult to determine if these were duplicate listings or the individuals had taken more than one product in the month. Also, since descriptive information on the form, strength, and dosage of prescription medicines was not collected it was difficult to determine if these were reasons for the duplications. Hence, most of the duplicates have been left in the file.

Up to three drug class codes (i.e., primary, secondary, and tertiary) were assigned to each prescription medication that a respondent reported. These 4-digit codes came from the National Drug Code Directory prepared by the Product Information Management Branch of the Food and Drug Administration. See Appendix 2 for a listing of the drug class codes and descriptions.

Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. For example, all cardiovascular drugs that were beta-adrenergic blocking agents were assigned the drug class code for "Beta blockers" (512). Additional drug class codes were assigned based on the reason the respondent reported for taking the medication, for example, "Antiarrhythmics" (502) or "Antihypertensives" (506). Another example is the drug "Diazepam". The primary drug class code for "Diazepam" is sedative or hypnotic (626). If the respondent reported any of the following reasons for taking the drug, the drug class fields were also coded with these reasons: anxiety (627), muscle spasms (1373), or convulsive disorder (1374). If the reason the respondent gave did not relate to any of the actions of the drug, then only the medication-specific class code was assigned.

There are instances where the prescription medication product code and standard generic name are coded as "blank but applicable" (8-fill), but there is a valid primary drug class code. In these cases, the medication name and/or health condition that the respondent reported provided sufficient information in order to assign a drug class code.

ICD-9-CM codes were used to classify the health problem respondents gave for taking the prescription medicine. In general, the health problems were coded to the fourth digit ICD-9-CM level of specificity, but in some cases the highest level of specificity was only three digits and in other cases the level of specificity was five digits. See the notes associated with this variable in the data file layout for a detailed discussion of the ICD-9-CM codes. See Appendix 3 for a listing of the ICD-9-CM codes and descriptions.

As described earlier there were respondents who reported taking a prescription medicine but did not give a reason why they took the medicine. In these instances the ICD-9 codes are coded as "blank but applicable" (8-fill) or "don't know" (9-fill). On the other hand, there were respondents who reported

a health problem but did not report the medication they were taking or NCHS staff could not identify it. In these cases the prescription medication product code, and sometimes the drug class codes, are coded as "blank but applicable" (8-fill) or "don't know" (9-fill), but there is an ICD-9 code listed.

For each prescription medicine reported, respondents were also asked how long they had been taking the medicine. See the notes associated with this variable in the data file layout for a detailed discussion of this variable. When medicines were moved from the dietary supplements section to the prescription medicine section some of the categories for duration of use did not correspond. A response of "less than one month" in the supplements section was changed to "blank but applicable" (8-fill) in prescription medicine section.

Household Questionnaire: Antacids

During the household interview survey respondents were asked a series of questions about use of non-prescription antacids in the past month. If respondents reported taking an antacid, they were asked the number of antacids they took. For each antacid reported, the interviewer asked to see the antacid container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Respondents were also asked how often they took each antacid in the past month, their dosage, and the duration of use of the antacid. Analysts should be aware, however, that there may be respondents who reported taking antacids, but who did not answer some or all of the remaining questions about the antacids. In addition, respondents may have said they took an antacid and answered all the subsequent questions, but did not know the name of the antacid or NCHS staff could not identify the name of the product. In both cases, the missing fields are coded as "blank but applicable" (8-fill) or "don't know" (9-fill), whichever was applicable.

All prescription antacids were moved to the prescription medication section and all non-prescription antacids were moved to this section of the survey. However, some products that are currently available without prescription (e.g., "Zantac"), were only available by prescription at the time of the survey. These types of products were left with the prescription medicines. Cold/cough preparations, anti-diarrheals, laxatives and other non-prescription medications, originally reported in this section, were moved to the non-prescription medication section. Also, psyllium-containing fiber products were moved to the dietary supplement section (see the dietary supplements documentation for details). The household youth questionnaire did not contain a section asking about antacid use. Therefore, calcium-containing antacids that were reported in the supplements section of the youth questionnaire were retained there since NCHS staff assumed respondents were taking them as a source of calcium.

Efforts were made to identify the antacids taken using the names, manufacturers and dosage information (liquid vs. tablet) that respondents reported. From the responses, a standardized list of antacids was created and includes specific brand name antacids, as well for defaults for incomplete brand names (e.g., Mylanta - Type Not Specified), generic product-type names (e.g., Calcium Antacid - Type Not Specified), and non-specific antacids (e.g., Other Antacids). Responses were then recoded from the standardized list of antacid names. Responses that appeared to be antacids but which could not be further identified, as well as various generic antacid responses, were coded as "Other

Antacids". If staff could not identify the antacid or if the respondent did not know the name of the antacid, the standardized name was recoded to "blank but applicable" (8-fill) or "don't know" (9-fill), respectively. A three-digit product code was associated with each of the standardized antacid names. The list of the standardized antacid names and their associated product codes can be found in Appendix 4.

In some cases it may appear as though respondents reported the same antacid more than once, but the dosages, frequency, or duration of use for each product may be different from each other. Since it was not clear if these were duplicate listings or different patterns of use of these products, the duplicates were left in the file.

For each antacid reported, respondents were also asked how often they took each antacid in the past month, their dosage, and the duration of use of the antacid. See the notes associated with each of these variables in the data file layout for a detailed discussion of each variable.

When antacids that were originally reported as prescription medicines were moved to the antacids section during the editing process, some fields were coded with 8-fills. Specifically, the prescription medicine section did not ask questions about the frequency of use and the dosage of the medicines taken. Therefore, the frequency of use and dosage fields (X15-X16) were coded as "blank but applicable" (8-fill) .

Household Questionnaire: Non-prescription Pain Relief Medicines

During the household interview survey respondents were asked if they used non-prescription pain relief medicines in the past month and how frequently they took them. The first question dealt with aspirin, the second with acetaminophen, and the third with ibuprofen. The remaining four questions were a catch-all for other non-prescription medicines respondents reported. NCHS staff classified their responses into one of 8 possible product-type categories, and these categories are listed in the last four questions. Analysts are cautioned that the product-type category "Other ingested pain medications" (1) includes products that contain aspirin, acetaminophen, or combinations of these two analgesics that were not listed in X18a or X18b, along with other analgesic products. Analysts should also be aware that there were respondents who reported taking non-prescription medicines, but did not know how frequently they took them, in which case the frequency variable is coded as "blank but applicable" (8-fill). If the respondent did not know if they took other non-prescription medicines the use question was coded as "don't know" (9-fill) and the frequency was left blank. Dietary supplement, prescription medicine, and antacid responses were moved to those respective sections. However, if "Alka-Seltzer" was reported in this section it was left here since it was assumed that it was taken for relief of pain, not as an antacid.

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
HOUSEHOLD SCREENER QUESTIONNAIRE (HSQ)		
GENERAL INFORMATION		
Respondent identification number	SEQN	1-5
HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)		
SECTION X. VITAMIN, MINERAL, AND MEDICINE USAGE		
Taken vitamins/minerals in past month	HAX1A	6
Taken prescrip ^t n medicines in past month	HAX1B	7
Taken antacids in past month	HAX1C	8
How many vitamins/minerals taken	HAX2A	9-10
How many prescription medicines taken	HAX2B	11-12
How many antacids taken	HAX2C	13-14
Certainty index code-1st	HAX3CG	15-16
Product class-1st	HAX3DG	17-18
How often did you take in past month-1st	HAX6SG	19-22
How long been taking (month)-1st	HAX8SG	23-26
Certainty index code-2nd	HAX3CH	27-28
Product class-2nd	HAX3DH	29-30
How often did you take in past month-2nd	HAX6SH	31-34
How long been taking (month)-2nd	HAX8SH	35-38
Certainty index code-3rd	HAX3CI	39-40
Product class-3rd	HAX3DI	41-42
How often did you take in past month-3rd	HAX6SI	43-46
How long been taking (month)-3rd	HAX8SI	47-50
Certainty index code-4th	HAX3CJ	51-52
Product class-4th	HAX3DJ	53-54
How often did you take in past month-4th	HAX6SJ	55-58
How long been taking (month)-4th	HAX8SJ	59-62
Certainty index code-5th	HAX3CK	63-64
Product class-5th	HAX3DK	65-66
How often did you take in past month-5th	HAX6SK	67-70
How long been taking (month)-5th	HAX8SK	71-74
Certainty index code-6th	HAX3CL	75-76
Product class-6th	HAX3DL	77-78

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
How often did you take in past month-6th	HAX6SL	79-82
How long been taking (month)-6th	HAX8SL	83-86
Certainty index code-7th	HAX3CM	87-88
Product class-7th	HAX3DM	89-90
How often did you take in past month-7th	HAX6SM	91-94
How long been taking (month)-7th	HAX8SM	95-98
Certainty index code-8th	HAX3CN	99-100
Product class-8th	HAX3DN	101-102
How often did you take in past month-8th	HAX6SN	103-106
How long been taking (month)-8th	HAX8SN	107-110
Certainty index code-9th	HAX3CO	111-112
Product class-9th	HAX3DO	113-114
How often did you take in past month-9th	HAX6SO	115-118
How long been taking (month)-9th	HAX8SO	119-122
Certainty index code-10th	HAX3CP	123-124
Product class-10th	HAX3DP	125-126
How often did you take in past mnth-10th	HAX6SP	127-130
How long been taking (month)-10th	HAX8SP	131-134
Certainty index code-11th	HAX3CQ	135-136
Product class-11th	HAX3DQ	137-138
How often did you take in past mnth-11th	HAX6SQ	139-142
How long been taking (month)-11th	HAX8SQ	143-146
Certainty index code-12th	HAX3CR	147-148
Product class-12th	HAX3DR	149-150
How often did you take in past mnth-12th	HAX6SR	151-154
How long been taking (month)-12th	HAX8SR	155-158
Certainty index code-13th	HAX3CS	159-160
Product class-13th	HAX3DS	161-162
How often did you take in past mnth-13th	HAX6SS	163-166
How long been taking (month)-13th	HAX8SS	167-170
Certainty index code-14th	HAX3CT	171-172
Product class-14th	HAX3DT	173-174
How often did you take in past mnth-14th	HAX6ST	175-178
How long been taking (month)-14th	HAX8ST	179-182
Certainty index code-15th	HAX3CU	183-184
Product class-15th	HAX3DU	185-186
How often did you take in past mnth-15th	HAX6SU	187-190
How long been taking (month)-15th	HAX8SU	191-194
Certainty index code-16th	HAX3CV	195-196

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
Product class-16th	HAX3DV	197-198
How often did you take in past mnth-16th	HAX6SV	199-202
How long been taking (month)-16th	HAX8SV	203-206
Certainty index code-17th	HAX3CW	207-208
Product class-17th	HAX3DW	209-210
How often did you take in past mnth-17th	HAX6SW	211-214
How long been taking (month)-17th	HAX8SW	215-218
Primary drug class code-1st	HAX9DG	219-222
Secondary drug class code-1st	HAX9EG	223-226
Tertiary drug class code-1st	HAX9FG	227-230
ICD-9-CM code-1st	HAX11AG	231-236
For how long been taking (days)-1st	HAX12SG	237-241
Primary drug class code-2nd	HAX9DH	242-245
Secondary drug class code-2nd	HAX9EH	246-249
Tertiary drug class code-2nd	HAX9FH	250-253
ICD-9-CM code-2nd	HAX11AH	254-259
For how long been taking (days)-2nd	HAX12SH	260-264
Primary drug class code-3rd	HAX9DI	265-268
Secondary drug class code-3rd	HAX9EI	269-272
Tertiary drug class code-3rd	HAX9FI	273-276
ICD-9-CM code-3rd	HAX11AI	277-282
For how long been taking (days)-3rd	HAX12SI	283-287
Primary drug class code-4th	HAX9DJ	288-291
Secondary drug class code-4th	HAX9EJ	292-295
Tertiary drug class code-4th	HAX9FJ	296-299
ICD-9-CM code-4th	HAX11AJ	300-305
For how long been taking (days)-4th	HAX12SJ	306-310
Primary drug class code-5th	HAX9DK	311-314
Secondary drug class code-5th	HAX9EK	315-318
Tertiary drug class code-5th	HAX9FK	319-322
ICD-9-CM code-5th	HAX11AK	323-328
For how long been taking (days)-5th	HAX12SK	329-333
Primary drug class code-6th	HAX9DL	334-337
Secondary drug class code-6th	HAX9EL	338-341
Tertiary drug class code-6th	HAX9FL	342-345
ICD-9-CM code-6th	HAX11AL	346-351
For how long been taking (days)-6th	HAX12SL	352-356
Primary drug class code-7th	HAX9DM	357-360
Secondary drug class code-7th	HAX9EM	361-364

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
Tertiary drug class code-7th	HAX9FM	365-368
ICD-9-CM code-7th	HAX11AM	369-374
For how long been taking (days)-7th	HAX12SM	375-379
Primary drug class code-8th	HAX9DN	380-383
Secondary drug class code-8th	HAX9EN	384-387
Tertiary drug class code-8th	HAX9FN	388-391
ICD-9-CM code-8th	HAX11AN	392-397
For how long been taking (days)-8th	HAX12SN	398-402
Primary drug class code-9th	HAX9DO	403-406
Secondary drug class code-9th	HAX9EO	407-410
Tertiary drug class code-9th	HAX9FO	411-414
ICD-9-CM code-9th	HAX11AO	415-420
For how long been taking (days)-9th	HAX12SO	421-425
Primary drug class code-10th	HAX9DP	426-429
Secondary drug class code-10th	HAX9EP	430-433
Tertiary drug class code-10th	HAX9FP	434-437
ICD-9-CM code-10th	HAX11AP	438-443
For how long been taking (days)-10th	HAX12SP	444-448
Primary drug class code-11th	HAX9DQ	449-452
Secondary drug class code-11th	HAX9EQ	453-456
Tertiary drug class code-11th	HAX9FQ	457-460
ICD-9-CM code-11th	HAX11AQ	461-466
For how long been taking (days)-11th	HAX12SQ	467-471
Primary drug class code-12th	HAX9DR	472-475
Secondary drug class code-12th	HAX9ER	476-479
Tertiary drug class code-12th	HAX9FR	480-483
ICD-9-CM code-12th	HAX11AR	484-489
For how long been taking (days)-12th	HAX12SR	490-494
Primary drug class code-13th	HAX9DS	495-498
Secondary drug class code-13th	HAX9ES	499-502
Tertiary drug class code-13th	HAX9FS	503-506
ICD-9-CM code-13th	HAX11AS	507-512
For how long been taking (days)-13th	HAX12SS	513-517
Primary drug class code-14th	HAX9DT	518-521
Secondary drug class code-14th	HAX9ET	522-525
Tertiary drug class code-14th	HAX9FT	526-529
ICD-9-CM code-14th	HAX11AT	530-535
For how long been taking (days)-14th	HAX12ST	536-540
Primary drug class code-15th	HAX9DU	541-544

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
Secondary drug class code-15th	HAX9EU	545-548
Tertiary drug class code-15th	HAX9FU	549-552
ICD-9-CM code-15th	HAX11AU	553-558
For how long been taking (days)-15th	HAX12SU	559-563
Primary drug class code-16th	HAX9DV	564-567
Secondary drug class code-16th	HAX9EV	568-571
Tertiary drug class code-16th	HAX9FV	572-575
ICD-9-CM code-16th	HAX11AV	576-581
For how long been taking (days)-16th	HAX12SV	582-586
Antacid identification code-1st	HAX13AG	587-589
How often did you take in past month-1st	HAX15SG	590-593
How much did you take ea time (quan)-1st	HAX16AG	594-595
How much did you take ea time (unit)-1st	HAX16A1G	596-597
How long been taking (months)-1st	HAX17SG	598-601
Antacid identification code-2nd	HAX13AH	602-604
How often did you take in past month-2nd	HAX15SH	605-608
How much did you take ea time (quan)-2nd	HAX16AH	609-610
How much did you take ea time (unit)-2nd	HAX16A1H	611-612
How long been taking (months)-2nd	HAX17SH	613-616
Antacid identification code-3rd	HAX13AI	617-619
How often did you take in past month-3rd	HAX15SI	620-623
How much did you take ea time (quan)-3rd	HAX16AI	624-625
How much did you take ea time (unit)-3rd	HAX16A1I	626-627
How long been taking (months)-3rd	HAX17SI	628-631
Antacid identification code-4th	HAX13AJ	632-634
How often did you take in past month-4th	HAX15SJ	635-638
How much did you take ea time (quan)-4th	HAX16AJ	639-640
How much did you take ea time (unit)-4th	HAX16A1J	641-642
How long been taking (months)-4th	HAX17SJ	643-646

SECTION X. VITAMIN, MINERAL, AND MEDICINE USAGE

Taken aspirin, etc. in past month	HAX18A	647
How often did you take in past month	HAX19AS	648-650
Taken acetaminophen, etc. in past month	HAX18B	651
How often did you take in past month	HAX19BS	652-654
Taken ibuprofen, etc. in past month	HAX18C	655
How often did you take in past month	HAX19CS	656-658

NHANES III Household Adult Data File Index
Including demographic, family, and survey weighting data

Description	Variable Name	Positions
Taken other pain rel. in past month-1st	HAX18D	659
Other pain rel. product type-1st	HAX18DB	660-661
How often did you take in past month-1st	HAX19DS	662-664
Taken other pain rel. in past month-2nd	HAX18E	665
Other pain rel. product type-2nd	HAX18EB	666-667
How often did you take in past month-2nd	HAX19ES	668-670
Taken other pain rel. in past month-3rd	HAX18F	671
Other pain rel. product type-3rd	HAX18FB	672-673
How often did you take in past month-3rd	HAX19FS	674-676
Taken other pain rel. in past month-4th	HAX18G	677
Other pain rel. product type-4th	HAX18GB	678-679
How often did you take in past month-4th	HAX19GS	680-682

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
<p>The following questions concern your use of vitamins, minerals, medicines, and certain products the past month.</p>			
HAX1A	6	<p>Have you taken any vitamins or minerals in the past month? Please include those that are prescribed by a doctor and those that are not prescribed? DO NOT INCLUDE TOPICAL VITAMINS.</p>	See note
	7381	1 Yes	
	12636	2 No	
	26	8 Blank but applicable	
	7	9 Don't know	
HAX1B	7	<p>Have you taken or used any medicines for which a doctor's or dentist's prescription is needed, in the past month? This includes any products which cannot be obtained without a doctor's or dentist's prescription. Include those medicines you may have already mentioned. DO NOT INCLUDE PRESCRIPTION VITAMINS WHICH SHOULD BE RECORDED AT HAX1A.</p>	See note
	9179	1 Yes	
	10835	2 No	
	28	8 Blank but applicable	
	8	9 Don't know	
HAX1C	8	<p>Have you taken antacids in the past month? INCLUDE PRESCRIPTION ANTACIDS HERE.</p>	See note
	3865	1 Yes	
	16067	2 No	
	85	8 Blank but applicable	
	33	9 Don't know	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
		CHECK ITEM. REFER TO RESPONSES IN HAX1A-1C.	
		IF ANY YES: May I see the containers for all of the (vitamins and minerals/ prescription medicines/ antacids) you took in the past month?	
		Also, if there are things that you need to do at this time such as going to the bathroom, please do so now so that I will be able to take your pulse and blood pressure immediately after the next section is completed.	
		IF NECESSARY, ASK SP TO MOVE TO A SUITABLE LOCATION TO RECORD LABEL INFORMATION AND TO TAKE THE PULSE AND BLOOD PRESSURE READINGS.	
9-10 HAX2A	7381 26 12643	Number of vitamins/minerals reported 01-17 88 Blank but applicable Blank	See note
11-12 HAX2B	9179 28 10843	Number of prescription medicines reported 01-16 88 Blank but applicable Blank	See note
13-14 HAX2C	3484 344 32 5 85 16100	Number of antacids reported 01 02 03 04 88 Blank but applicable Blank	See note

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
		Vitamin and mineral supplements	
15-16 HAX3CG		Certainty index code (1st supplement reported)	See note
	4001	01 Match with high degree of certainty	
	754	02 Match with reasonable degree of certainty	
	1417	03 Match to product ingredients only (not amounts)	
	1017	04 Match to product type only (not exact amounts)	
	110	05 No match - unidentified supplement	
	82	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	12643	Blank	
17-18 HAX3DG		Product class (1st supplement reported)	See note
	997	01 Vitamin supplement - single nutrient	
	1537	02 Vitamin supplement - multiple nutrient	
	1163	03 Mineral supplement - single nutrient	
	97	04 Mineral supplement - multiple nutrient	
	2999	05 Vitamin - mineral combination	
	104	06 Other dietary supplement with vitamin(s)/mineral(s)	
	332	07 Other dietary supplement	
	178	88 Blank but applicable	
	12643	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
19-22 HAX6SG		How often did you take/use (PRODUCT) in the past month? (1st supplement reported)	See note
	6782	0001-0760	
	620	8888 Blank but applicable	
	5	9999 Don't know	
	12643	Blank	
23-26 HAX8SG		For how long have you been taking/using this type of product? (months) (1st supplement reported)	See note
	6742	0001-1164	
	502	7777 Less than one month	
	59	8888 Blank but applicable	
	104	9999 Don't know	
	12643	Blank	
27-28 HAX3CH		Certainty index code (2nd supplement reported)	See note
	950	01 Match with high degree of certainty	
	138	02 Match with reasonable degree of certainty	
	1190	03 Match to product ingredients only (not amounts)	
	303	04 Match to product type only (not exact amounts)	
	38	05 No match - unidentified supplement	
	27	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	17378	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
29-30 HAX3DH		Product class (2nd supplement reported)	See note
	929	01 Vitamin supplement - single nutrient	
	357	02 Vitamin supplement - multiple nutrient	
	526	03 Mineral supplement - single nutrient	
	60	04 Mineral supplement - multiple nutrient	
	447	05 Vitamin - mineral combination	
	45	06 Other dietary supplement with vitamin(s)/mineral(s)	
	229	07 Other dietary supplement	
	79	88 Blank but applicable	
	17378	Blank	
31-34 HAX6SH		How often did you take/use (PRODUCT) in the past month? (2nd supplement reported)	See note
	2504	0001-0699	
	166	8888 Blank but applicable	
	2	9999 Don't know	
	17378	Blank	
35-38 HAX8SH		For how long have you been taking/using this type of product? (months) (2nd supplement reported)	See note
	2454	0001-0600	
	147	7777 Less than one month	
	42	8888 Blank but applicable	
	29	9999 Don't know	
	17378	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
39-40 HAX3CI		Certainty index code (3rd supplement reported)	See note
	345	01 Match with high degree of certainty	
	36	02 Match with reasonable degree of certainty	
	617	03 Match to product ingredients only (not amounts)	
	99	04 Match to product type only (not exact amounts)	
	24	05 No match - unidentified supplement	
	19	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	18884	Blank	
41-42 HAX3DI		Product class (3rd supplement reported)	See note
	550	01 Vitamin supplement - single nutrient	
	119	02 Vitamin supplement - multiple nutrient	
	151	03 Mineral supplement - single nutrient	
	27	04 Mineral supplement - multiple nutrient	
	91	05 Vitamin - mineral combination	
	29	06 Other dietary supplement with vitamin(s)/mineral(s)	
	134	07 Other dietary supplement	
	65	88 Blank but applicable	
	18884	Blank	
43-46 HAX6SI		How often did you take/use (PRODUCT) in the past month? (3rd supplement reported)	See note
	1105	0001-0243	
	61	8888 Blank but applicable	
	18884	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
47-50 HAX8SI		For how long have you been taking/using this type of product? (months) (3rd supplement reported)	See note
	1080	0001-0600	
	46	7777 Less than one month	
	30	8888 Blank but applicable	
	10	9999 Don't know	
	18884	Blank	
51-52 HAX3CJ		Certainty index code (4th supplement reported)	See note
	177	01 Match with high degree of certainty	
	20	02 Match with reasonable degree of certainty	
	334	03 Match to product ingredients only (not amounts)	
	44	04 Match to product type only (not exact amounts)	
	20	05 No match - unidentified supplement	
	10	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19419	Blank	
53-54 HAX3DJ		Product class (4th supplement reported)	See note
	307	01 Vitamin supplement - single nutrient	
	41	02 Vitamin supplement - multiple nutrient	
	82	03 Mineral supplement - single nutrient	
	12	04 Mineral supplement - multiple nutrient	
	60	05 Vitamin - mineral combination	
	9	06 Other dietary supplement with vitamin(s)/mineral(s)	
	68	07 Other dietary supplement	
	52	88 Blank but applicable	
	19419	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
55-58 HAX6SJ		How often did you take/use (PRODUCT) in the past month? (4th supplement reported)	See note
	591	0001-0456	
	39	8888 Blank but applicable	
	1	9999 Don't know	
	19419	Blank	
59-62 HAX8SJ		For how long have you been taking/using this type of product? (months) (4th supplement reported)	See note
	571	0001-0516	
	27	7777 Less than one month	
	29	8888 Blank but applicable	
	4	9999 Don't know	
	19419	Blank	
63-64 HAX3CK		Certainty index code (5th supplement reported)	See note
	99	01 Match with high degree of certainty	
	8	02 Match with reasonable degree of certainty	
	189	03 Match to product ingredients only (not amounts)	
	32	04 Match to product type only (not exact amounts)	
	14	05 No match - unidentified supplement	
	4	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19678	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
65-66 HAX3DK		Product class (5th supplement reported)	See note
	155	01 Vitamin supplement - single nutrient	
	38	02 Vitamin supplement - multiple nutrient	
	51	03 Mineral supplement - single nutrient	
	3	04 Mineral supplement - multiple nutrient	
	24	05 Vitamin - mineral combination	
	6	06 Other dietary supplement with vitamin(s)/mineral(s)	
	54	07 Other dietary supplement	
	41	88 Blank but applicable	
	19678	Blank	
67-70 HAX6SK		How often did you take/use (PRODUCT) in the past month? (5th supplement reported)	See note
	342	0001-0243	
	30	8888 Blank but applicable	
	19678	Blank	
71-74 HAX8SK		For how long have you been taking/using this type of product? (months) (5th supplement reported)	See note
	331	0001-0528	
	10	7777 Less than one month	
	28	8888 Blank but applicable	
	3	9999 Don't know	
	19678	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
75-76 HAX3CL		Certainty index code (6th supplement reported)	See note
	50	01 Match with high degree of certainty	
	6	02 Match with reasonable degree of certainty	
	118	03 Match to product ingredients only (not amounts)	
	18	04 Match to product type only (not exact amounts)	
	7	05 No match - unidentified supplement	
	7	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19818	Blank	
77-78 HAX3DL		Product class (6th supplement reported)	See note
	95	01 Vitamin supplement - single nutrient	
	22	02 Vitamin supplement - multiple nutrient	
	26	03 Mineral supplement - single nutrient	
	1	04 Mineral supplement - multiple nutrient	
	14	05 Vitamin - mineral combination	
	2	06 Other dietary supplement with vitamin(s)/mineral(s)	
	33	07 Other dietary supplement	
	39	88 Blank but applicable	
	19818	Blank	
79-82 HAX6SL		How often did you take/use (PRODUCT) in the past month? (6th supplement reported)	See note
	193	0002-0122	
	8	0009	
	31	8888 Blank but applicable	
	19818	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
83-86 HAX8SL		For how long have you been taking/using this type of product? (months) (6th supplement reported)	See note
	198	0001-0480	
	6	7777 Less than one month	
	28	8888 Blank but applicable	
	19818	Blank	
87-88 HAX3CM		Certainty index code (7th supplement reported)	See note
	25	01 Match with high degree of certainty	
	3	02 Match with reasonable degree of certainty	
	72	03 Match to product ingredients only (not amounts)	
	11	04 Match to product type only (not exact amounts)	
	3	05 No match - unidentified supplement	
	3	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19907	Blank	
89-90 HAX3DM		Product class (7th supplement reported)	See note
	51	01 Vitamin supplement - single nutrient	
	11	02 Vitamin supplement - multiple nutrient	
	19	03 Mineral supplement - single nutrient	
	7	05 Vitamin - mineral combination	
	2	06 Other dietary supplement with vitamin(s)/mineral(s)	
	22	07 Other dietary supplement	
	31	88 Blank but applicable	
	19907	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
91-94 HAX6SM		How often did you take/use (PRODUCT) in the past month? (7th supplement reported)	See note
	1	0004	
	2	0006	
	2	0009	
	4	0013	
	1	0015	
	2	0017	
	1	0020	
	88	0030	
	7	0061	
	4	0091	
	1	0182	
	1	0304	
	29	8888 Blank but applicable	
	19907	Blank	
95-98 HAX8SM		For how long have you been taking/using this type of product? (months) (7th supplement reported)	See note
	113	0001-0480	
	2	7777 Less than one month	
	28	8888 Blank but applicable	
	19907	Blank	
99-100 HAX3CN		Certainty index code (8th supplement reported)	See note
	8	01 Match with high degree of certainty	
	1	02 Match with reasonable degree of certainty	
	45	03 Match to product ingredients only (not amounts)	
	4	04 Match to product type only (not exact amounts)	
	3	05 No match - unidentified supplement	
	2	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19961	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
101-102 HAX3DN		Product class (8th supplement reported)	See note
	25	01 Vitamin supplement - single nutrient	
	10	02 Vitamin supplement - multiple nutrient	
	9	03 Mineral supplement - single nutrient	
	2	04 Mineral supplement - multiple nutrient	
	1	05 Vitamin - mineral combination	
	11	07 Other dietary supplement	
	31	88 Blank but applicable	
	19961	Blank	
103-106 HAX6SN		How often did you take/use (PRODUCT) in the past month? (8th supplement reported)	See note
	1	0002	
	1	0004	
	3	0009	
	2	0013	
	1	0014	
	1	0015	
	1	0020	
	1	0022	
	41	0030	
	6	0061	
	2	0091	
	1	0182	
	28	8888 Blank but applicable	
	19961	Blank	
107-110 HAX8SN		For how long have you been taking/using this type of product? (months) (8th supplement reported)	See note
	59	0001-0360	
	2	7777 Less than one month	
	28	8888 Blank but applicable	
	19961	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
111-112 HAX3CO		Certainty index code (9th supplement reported)	See note
	7	01 Match with high degree of certainty	
	1	02 Match with reasonable degree of certainty	
	30	03 Match to product ingredients only (not amounts)	
	2	04 Match to product type only (not exact amounts)	
	2	05 No match - unidentified supplement	
	2	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19980	Blank	
113-114 HAX3DO		Product class (9th supplement reported)	See note
	17	01 Vitamin supplement - single nutrient	
	3	02 Vitamin supplement - multiple nutrient	
	9	03 Mineral supplement - single nutrient	
	1	04 Mineral supplement - multiple nutrient	
	4	05 Vitamin - mineral combination	
	1	06 Other dietary supplement with vitamin(s)/mineral(s)	
	6	07 Other dietary supplement	
	29	88 Blank but applicable	
	19980	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
115-118 HAX6SO		How often did you take/use (PRODUCT) in the past month? (9th supplement reported)	See note
	1	0002	
	2	0009	
	3	0013	
	28	0030	
	7	0061	
	1	0091	
	28	8888 Blank but applicable	
	19980	Blank	
119-122 HAX8SO		For how long have you been taking/using this type of product? (months) (9th supplement reported)	See note
	41	0001-0516	
	2	7777 Less than one month	
	27	8888 Blank but applicable	
	19980	Blank	
123-124 HAX3CP		Certainty index code (10th supplement reported)	See note
	5	01 Match with high degree of certainty	
	18	03 Match to product ingredients only (not amounts)	
	5	04 Match to product type only (not exact amounts)	
	4	05 No match - unidentified supplement	
	1	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	19991	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
125-126 HAX3DP		Product class (10th supplement reported)	See note
	8	01 Vitamin supplement - single nutrient	
	4	02 Vitamin supplement - multiple nutrient	
	7	03 Mineral supplement - single nutrient	
	5	05 Vitamin - mineral combination	
	1	06 Other dietary supplement with vitamin(s)/mineral(s)	
	5	07 Other dietary supplement	
	29	88 Blank but applicable	
	19991	Blank	
127-130 HAX6SP		How often did you take/use (PRODUCT) in the past month? (10th supplement reported)	See note
	1	0002	
	1	0005	
	1	0009	
	2	0013	
	1	0014	
	22	0030	
	3	0061	
	1	0091	
	27	8888 Blank but applicable	
	19991	Blank	
131-134 HAX8SP		For how long have you been taking/using this type of product? (months) (10th supplement reported)	See note
	30	0001-0360	
	2	7777 Less than one month	
	27	8888 Blank but applicable	
	19991	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
135-136 HAX3CQ		Certainty index code (11th supplement reported)	See note
	4	01 Match with high degree of certainty	
	12	03 Match to product ingredients only (not amounts)	
	3	04 Match to product type only (not exact amounts)	
	1	05 No match - unidentified supplement	
	1	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	20003	Blank	
137-138 HAX3DQ		Product class (11th supplement reported)	See note
	5	01 Vitamin supplement - single nutrient	
	2	02 Vitamin supplement - multiple nutrient	
	6	03 Mineral supplement - single nutrient	
	2	05 Vitamin - mineral combination	
	4	07 Other dietary supplement	
	28	88 Blank but applicable	
	20003	Blank	
139-142 HAX6SQ		How often did you take/use (PRODUCT) in the past month? (11th supplement reported)	See note
	1	0002	
	1	0003	
	2	0013	
	14	0030	
	1	0061	
	1	0091	
	27	8888 Blank but applicable	
	20003	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
143-146 HAX8SQ		For how long have you been taking/using this type of product? (months) (11th supplement reported)	See note
	19	0002-0300	
	1	7777 Less than one month	
	27	8888 Blank but applicable	
	20003	Blank	
147-148 HAX3CR		Certainty index code (12th supplement reported)	See note
	1	01 Match with high degree of certainty	
	1	02 Match with reasonable degree of certainty	
	11	03 Match to product ingredients only (not amounts)	
	1	04 Match to product type only (not exact amounts)	
	1	05 No match - unidentified supplement	
	1	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	20008	Blank	
149-150 HAX3DR		Product class (12th supplement reported)	See note
	5	01 Vitamin supplement - single nutrient	
	1	02 Vitamin supplement - multiple nutrient	
	5	03 Mineral supplement - single nutrient	
	1	05 Vitamin - mineral combination	
	2	07 Other dietary supplement	
	28	88 Blank but applicable	
	20008	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
151-154 HAX6SR		How often did you take/use (PRODUCT) in the past month? (12th supplement reported)	See note
	1	0009	
	2	0013	
	1	0014	
	9	0030	
	2	0061	
	27	8888 Blank but applicable	
	20008	Blank	
155-158 HAX8SR		For how long have you been taking/using this type of product? (months) (12th supplement reported)	See note
	1	0001	
	1	0006	
	1	0012	
	1	0024	
	1	0036	
	1	0060	
	2	0120	
	2	0144	
	3	0240	
	1	0348	
	28	8888 Blank but applicable	
	20008	Blank	
159-160 HAX3CS		Certainty index code (13th supplement reported)	See note
	1	01 Match with high degree of certainty	
	9	03 Match to product ingredients only (not amounts)	
	2	05 No match - unidentified supplement	
	26	88 Blank but applicable	
	20012	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
161-162 HAX3DS		Product class (13th supplement reported)	See note
	4	01 Vitamin supplement - single nutrient	
	1	02 Vitamin supplement - multiple nutrient	
	4	03 Mineral supplement - single nutrient	
	1	07 Other dietary supplement	
	28	88 Blank but applicable	
	20012	Blank	
163-166 HAX6SS		How often did you take/use (PRODUCT) in the past month? (13th supplement reported)	See note
	2	0013	
	9	0030	
	1	0061	
	26	8888 Blank but applicable	
	20012	Blank	
167-170 HAX8SS		For how long have you been taking/using this type of product? (months) (13th supplement reported)	See note
	1	0001	
	1	0002	
	1	0006	
	1	0024	
	1	0108	
	1	0120	
	2	0144	
	1	0180	
	1	0240	
	1	7777 Less than one month	
	27	8888 Blank but applicable	
	20012	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
171-172 HAX3CT		Certainty index code (14th supplement reported)	See note
	1	01 Match with high degree of certainty	
	5	03 Match to product ingredients only (not amounts)	
	1	05 No match - unidentified supplement	
	1	06 No match - too vague to identify as a supplement	
	26	88 Blank but applicable	
	20016	Blank	
173-174 HAX3DT		Product class (14th supplement reported)	See note
	3	01 Vitamin supplement - single nutrient	
	2	03 Mineral supplement - single nutrient	
	1	07 Other dietary supplement	
	28	88 Blank but applicable	
	20016	Blank	
175-178 HAX6ST		How often did you take/use (PRODUCT) in the past month? (14th supplement reported)	See note
	6	0030	
	2	0061	
	26	8888 Blank but applicable	
	20016	Blank	
179-182 HAX8ST		For how long have you been taking/using this type of product? (months) (14th supplement reported)	See note
	1	0012	
	1	0036	
	2	0144	
	1	0240	
	1	0348	
	2	0360	
	26	8888 Blank but applicable	
	20016	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
183-184 HAX3CU		Certainty index code (15th supplement reported)	See note
	1	01 Match with high degree of certainty	
	3	03 Match to product ingredients only (not amounts)	
	1	05 No match - unidentified supplement	
	26	88 Blank but applicable	
	20019	Blank	
185-186 HAX3DU		Product class (15th supplement reported)	See note
	2	01 Vitamin supplement - single nutrient	
	2	03 Mineral supplement - single nutrient	
	27	88 Blank but applicable	
	20019	Blank	
187-190 HAX6SU		How often did you take/use (PRODUCT) in the past month? (15th supplement reported)	See note
	5	0030	
	26	8888 Blank but applicable	
	20019	Blank	
191-194 HAX8SU		For how long have you been taking/using this type of product? (months) (15th supplement reported)	See note
	1	0048	
	1	0120	
	1	0144	
	1	0240	
	1	0360	
	26	8888 Blank but applicable	
	20019	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
195-196 HAX3CV		Certainty index code (16th supplement reported)	See note
	1	03	
	26	88 Blank but applicable	
	20023	Blank	
197-198 HAX3DV		Product class (16th supplement reported)	See note
	1	02 Vitamin supplement - multiple nutrient	
	26	88 Blank but applicable	
	20023	Blank	
199-202 HAX6SV		How often did you take/use (PRODUCT) in the past month? (16th supplement reported)	See note
	1	0030	
	26	8888 Blank but applicable	
	20023	Blank	
203-206 HAX8SV		For how long have you been taking/using this type of product? (months) (16th supplement reported)	See note
	1	0144	
	26	8888 Blank but applicable	
	20023	Blank	
207-208 HAX3CW		Certainty index code (17th supplement reported)	See note
	1	03 Match to product ingredients only (not amounts)	
	26	88 Blank but applicable	
	20023	Blank	
209-210 HAX3DW		Product class (17th supplement reported)	See note
	1	03 Mineral supplement - single nutrient	
	26	88 Blank but applicable	
	20023	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
211-214 HAX6SW		How often did you take/use (PRODUCT) in the past month? (17th supplement reported)	See note
	1	0030	
	26	8888 Blank but applicable	
	20023	Blank	
215-218 HAX8SW		For how long have you been taking/using this type of product? (months) (17th supplement reported)	See note
	1	0144	
	26	8888 Blank but applicable	
	20023	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
Prescription medicines			
219-222 HAX9DG		Primary drug class code (1st medication reported)	See note
	8900	0100-2100	
	195	8888 Blank but applicable	
	112	9999 Don't know	
	10843	Blank	
223-226 HAX9EG		Secondary drug class code (1st medication reported)	See note
	2101	0353-1900	
	6994	8888 Blank but applicable	
	112	9999 Don't know	
	10843	Blank	
227-230 HAX9FG		Tertiary drug class code (1st medication reported)	See note
	1	0348	
	110	0506	
	1	1270	
	8983	8888 Blank but applicable	
	112	9999 Don't know	
	10843	Blank	
231-236 HAX11AG		ICD-9-CM code (1st medication reported)	See note
	8955	V01.1-999.3	
	137	888888 Blank but applicable	
	115	999999 Don't know	
	10843	Blank	
237-241 HAX12SG		For how long have you been taking or using (MEDICINE)? (days) (1st medication reported)	See note
	9030	00001-23360	
	80	88888 Blank but applicable	
	97	99999 Don't know	
	10843	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
242-245 HAX9DH		Primary drug class code (2nd medication reported)	See note
	5353	0281-2100	
	160	8888 Blank but applicable	
	65	9999 Don't know	
	14472	Blank	
246-249 HAX9EH		Secondary drug class code (2nd medication reported)	See note
	1280	0121-1729	
	4233	8888 Blank but applicable	
	65	9999 Don't know	
	14472	Blank	
250-253 HAX9FH		Tertiary drug class code (2nd medication reported)	See note
	39	0506	
	1	1268	
	5473	8888 Blank but applicable	
	65	9999 Don't know	
	14472	Blank	
254-259 HAX11AH		ICD-9-CM code (2nd medication reported)	See note
	5355	V01.1-997.6	
	103	888888 Blank but applicable	
	120	999999 Don't know	
	14472	Blank	
260-264 HAX12SH		For how long have you been taking or using (MEDICINE)? (days) (2nd medication reported)	See note
	5423	00001-19345	
	61	88888 Blank but applicable	
	94	99999 Don't know	
	14472	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
265-268 HAX9DI		Primary drug class code (3rd medication reported)	See note
	3225	0118-2087	
	107	8888 Blank but applicable	
	32	9999 Don't know	
	16686	Blank	
269-272 HAX9EI		Secondary drug class code (3rd medication reported)	See note
	780	0353-1729	
	2552	8888 Blank but applicable	
	32	9999 Don't know	
	16686	Blank	
273-276 HAX9FI		Tertiary drug class code (3rd medication reported)	See note
	1	0503	
	15	0506	
	3316	8888 Blank but applicable	
	32	9999 Don't know	
	16686	Blank	
277-282 HAX11AI		ICD-9-CM code (3rd medication reported)	See note
	3176	V07.31-996.8	
	87	888888 Blank but applicable	
	101	999999 Don't know	
	16686	Blank	
283-287 HAX12SI		For how long have you been taking or using (MEDICINE)? (days) (3rd medication reported)	See note
	3217	00001-21900	
	53	88888 Blank but applicable	
	94	99999 Don't know	
	16686	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
288-291 HAX9DJ		Primary drug class code (4th medication reported)	See note
	1909	0300-2087	
	65	8888 Blank but applicable	
	11	9999 Don't know	
	18065	Blank	
292-295 HAX9EJ		Secondary drug class code (4th medication reported)	See note
	389	0353-1724	
	1585	8888 Blank but applicable	
	11	9999 Don't know	
	18065	Blank	
296-299 HAX9FJ		Tertiary drug class code (4th medication reported)	See note
	6	0506	
	1968	8888 Blank but applicable	
	11	9999 Don't know	
	18065	Blank	
300-305 HAX11AJ		ICD-9-CM code (4th medication reported)	See note
	1834	V07.4-995.3	
	68	888888 Blank but applicable	
	83	999999 Don't know	
	18065	Blank	
306-310 HAX12SJ		For how long have you been taking or using (MEDICINE)? (days) (4th medication reported)	See note
	1871	00001-18250	
	48	88888 Blank but applicable	
	66	99999 Don't know	
	18065	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
311-314 HAX9DK		Primary drug class code (5th medication reported)	See note
	1123	0300-2087	
	51	8888 Blank but applicable	
	8	9999 Don't know	
	18868	Blank	
315-318 HAX9EK		Secondary drug class code (5th medication reported)	See note
	180	0502-1724	
	994	8888 Blank but applicable	
	8	9999 Don't know	
	18868	Blank	
319-322 HAX9FK		Tertiary drug class code (5th medication reported)	See note
	1174	8888 Blank but applicable	
	8	9999 Don't know	
	18868	Blank	
323-328 HAX11AK		ICD-9-CM code (5th medication reported)	See note
	1076	V07.4-997.6	
	55	888888 Blank but applicable	
	51	999999 Don't know	
	18868	Blank	
329-333 HAX12SK		For how long have you been taking or using (MEDICINE)? (days) (5th medication reported)	See note
	1088	00001-20440	
	42	88888 Blank but applicable	
	52	99999 Don't know	
	18868	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
334-337 HAX9DL		Primary drug class code (6th medication reported)	See note
	658	0346-2087	
	43	8888 Blank but applicable	
	7	9999 Don't know	
	19342	Blank	
338-341 HAX9EL		Secondary drug class code (6th medication reported)	See note
	1	0353	
	2	0502	
	5	0503	
	67	0506	
	1	0507	
	2	0912	
	1	1037	
	2	1268	
	5	1566	
	3	1723	
	16	1724	
	596	8888 Blank but applicable	
	7	9999 Don't know	
	19342	Blank	
342-345 HAX9FL		Tertiary drug class code (6th medication reported)	See note
	1	0506	
	2	1271	
	698	8888 Blank but applicable	
	7	9999 Don't know	
	19342	Blank	
346-351 HAX11AL		ICD-9-CM code (6th medication reported)	See note
	638	V07.4-995.3	
	45	888888 Blank but applicable	
	25	999999 Don't know	
	19342	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
352-356 HAX12SL		For how long have you been taking or using (MEDICINE)? (days) (6th medication reported)	See note
	633	00001-14600	
	36	88888 Blank but applicable	
	39	99999 Don't know	
	19342	Blank	
357-360 HAX9DM		Primary drug class code (7th medication reported)	See note
	344	0346-1947	
	38	8888 Blank but applicable	
	2	9999 Don't know	
	19666	Blank	
361-364 HAX9EM		Secondary drug class code (7th medication reported)	See note
	1	0502	
	7	0503	
	36	0506	
	1	0507	
	1	0630	
	5	1566	
	11	1724	
	320	8888 Blank but applicable	
	2	9999 Don't know	
	19666	Blank	
365-368 HAX9FM		Tertiary drug class code (7th medication reported)	See note
	1	0506	
	381	8888 Blank but applicable	
	2	9999 Don't know	
	19666	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
369-374 HAX11AM		ICD-9-CM code (7th medication reported)	See note
	338	V07.4-959.1	
	37	888888 Blank but applicable	
	9	999999 Don't know	
	19666	Blank	
375-379 HAX12SM		For how long have you been taking or using (MEDICINE)? (days) (7th medication reported)	See note
	330	00001-17155	
	33	88888 Blank but applicable	
	21	99999 Don't know	
	19666	Blank	
380-383 HAX9DN		Primary drug class code (8th medication reported)	See note
	207	0346-2087	
	34	8888 Blank but applicable	
	19809	Blank	
384-387 HAX9EN		Secondary drug class code (8th medication reported)	See note
	1	0353	
	16	0506	
	1	0878	
	4	1724	
	219	8888 Blank but applicable	
	19809	Blank	
388-391 HAX9FN		Tertiary drug class code (8th medication reported)	See note
	241	8888 Blank but applicable	
	19809	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
392-397 HAX11AN		ICD-9-CM code (8th medication reported)	See note
	204	V07.4-995.3	
	34	888888 Blank but applicable	
	3	999999 Don't know	
	19809	Blank	
398-402 HAX12SN		For how long have you been taking or using (MEDICINE)? (days) (8th medication reported)	See note
	201	00004-14600	
	31	88888 Blank but applicable	
	9	99999 Don't know	
	19809	Blank	
403-406 HAX9DO		Primary drug class code (9th medication reported)	See note
	126	0348-1944	
	32	8888 Blank but applicable	
	19892	Blank	
407-410 HAX9EO		Secondary drug class code (9th medication reported)	See note
	1	0502	
	1	0503	
	4	0506	
	1	1274	
	1	1566	
	1	1723	
	3	1724	
	146	8888 Blank but applicable	
	19892	Blank	
411-414 HAX9FO		Tertiary drug class code (9th medication reported)	See note
	158	8888 Blank but applicable	
	19892	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
415-420 HAX11AO		ICD-9-CM code (9th medication reported)	See note
	121	V07.9-995.3	
	34	888888 Blank but applicable	
	3	999999 Don't know	
	19892	Blank	
421-425 HAX12SO		For how long have you been taking or using (MEDICINE)? (days) (9th medication reported)	See note
	121	00001-16060	
	32	88888 Blank but applicable	
	5	99999 Don't know	
	19892	Blank	
426-429 HAX9DP		Primary drug class code (10th medication reported)	See note
	71	0346-1947	
	29	8888 Blank but applicable	
	1	9999 Don't know	
	19949	Blank	
430-433 HAX9EP		Secondary drug class code (10th medication reported)	See note
	3	0506	
	2	1724	
	95	8888 Blank but applicable	
	1	9999 Don't know	
	19949	Blank	
434-437 HAX9FP		Tertiary drug class code (10th medication reported)	See note
	100	8888 Blank but applicable	
	1	9999 Don't know	
	19949	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
438-443 HAX11AP		ICD-9-CM code (10th medication reported)	See note
	70	V07.4-959.1	
	29	888888 Blank but applicable	
	2	999999 Don't know	
	19949	Blank	
444-448 HAX12SP		For how long have you been taking or using (MEDICINE)? (days) (10th medication reported)	See note
	67	00007-08030	
	29	88888 Blank but applicable	
	5	99999 Don't know	
	19949	Blank	
449-452 HAX9DQ		Primary drug class code (11th medication reported)	See note
	52	0347-1944	
	28	8888 Blank but applicable	
	1	9999 Don't know	
	19969	Blank	
453-456 HAX9EQ		Secondary drug class code (11th medication reported)	See note
	4	0506	
	1	1268	
	1	1724	
	74	8888 Blank but applicable	
	1	9999 Don't know	
	19969	Blank	
457-460 HAX9FQ		Tertiary drug class code (11th medication reported)	See note
	80	8888 Blank but applicable	
	1	9999 Don't know	
	19969	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
461-466 HAX11AQ		ICD-9-CM code (11th medication reported)	See note
	49	V07.4-995.3	
	31	888888 Blank but applicable	
	1	999999 Don't know	
	19969	Blank	
467-471 HAX12SQ		For how long have you been taking or using (MEDICINE)? (days) (11th medication reported)	See note
	51	00002-08030	
	28	88888 Blank but applicable	
	2	99999 Don't know	
	19969	Blank	
472-475 HAX9DR		Primary drug class code (12th medication reported)	See note
	32	0358-1947	
	29	8888 Blank but applicable	
	1	9999 Don't know	
	19988	Blank	
476-479 HAX9ER		Secondary drug class code (12th medication reported)	See note
	3	0506	
	1	1566	
	1	1724	
	56	8888 Blank but applicable	
	1	9999 Don't know	
	19988	Blank	
480-483 HAX9FR		Tertiary drug class code (12th medication reported)	See note
	61	8888 Blank but applicable	
	1	9999 Don't know	
	19988	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
484-489 HAX11AR		ICD-9-CM code (12th medication reported)	See note
	34	V07.4-995.3	
	28	888888 Blank but applicable	
	19988	Blank	
490-494 HAX12SR		For how long have you been taking or using (MEDICINE)? (days) (12th medication reported)	See note
	33	00030-08030	
	28	88888 Blank but applicable	
	1	99999 Don't know	
	19988	Blank	
495-498 HAX9DS		Primary drug class code (13th medication reported)	See note
	1	0358	
	1	0409	
	3	0507	
	1	0508	
	1	0514	
	2	0626	
	2	0874	
	1	0915	
	2	1036	
	1	1727	
	2	1940	
	28	8888 Blank but applicable	
	20005	Blank	
499-502 HAX9ES		Secondary drug class code (13th medication reported)	See note
	2	0506	
	1	1268	
	1	1724	
	41	8888 Blank but applicable	
	20005	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
503-506 HAX9FS		Tertiary drug class code (13th medication reported)	See note
	1	1271	
	44	8888 Blank but applicable	
	20005	Blank	
507-512 HAX11AS		ICD-9-CM code (13th medication reported)	See note
	16	250.0-786.0	
	28	888888 Blank but applicable	
	1	999999 Don't know	
	20005	Blank	
513-517 HAX12SS		For how long have you been taking or using (MEDICINE)? (days) (13th medication reported)	See note
	1	00061	
	1	00152	
	1	00243	
	1	00274	
	4	00365	
	1	00730	
	1	01095	
	2	01825	
	2	03650	
	1	05110	
	1	08030	
	28	88888 Blank but applicable	
	1	99999 Don't know	
	20005	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
518-521 HAX9DT		Primary drug class code (14th medication reported)	See note
	1	0514	
	1	1200	
	1	1374	
	1	1721	
	2	1727	
	1	1900	
	1	1944	
	29	8888 Blank but applicable	
	20013	Blank	
522-525 HAX9ET		Secondary drug class code (14th medication reported)	See note
	1	0506	
	1	1724	
	35	8888 Blank but applicable	
	20013	Blank	
526-529 HAX9FT		Tertiary drug class code (14th medication reported)	See note
	37	8888 Blank but applicable	
	20013	Blank	
530-535 HAX11AT		ICD-9-CM code (14th medication reported)	See note
	1	401.9	
	1	692.9	
	1	716.9	
	1	780.3	
	2	780.9	
	1	784.0	
	1	786.2	
	28	888888 Blank but applicable	
	1	995.3	
	20013	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
536-540 HAX12ST		For how long have you been taking or using (MEDICINE)? (days) (14th medication reported)	See note
	1	00014	
	1	00091	
	2	00243	
	1	00365	
	1	00730	
	1	01825	
	1	04380	
	1	05475	
	28	88888 Blank but applicable	
	20013	Blank	
541-544 HAX9DU		Primary drug class code (15th medication reported)	See note
	1	0626	
	1	0879	
	2	1036	
	1	1944	
	29	8888 Blank but applicable	
	20016	Blank	
545-548 HAX9EU		Secondary drug class code (15th medication reported)	See note
	34	8888 Blank but applicable	
	20016	Blank	
549-552 HAX9FU		Tertiary drug class code (15th medication reported)	See note
	34	8888 Blank but applicable	
	20016	Blank	
553-558 HAX11AU		ICD-9-CM code (15th medication reported)	See note
	2	250.0	
	1	473.9	
	2	799.2	
	29	888888 Blank but applicable	
	20016	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
559-563 HAX12SU		For how long have you been taking or using (MEDICINE)? (days) (15th medication reported)	See note
	2	00030	
	1	00243	
	1	00547	
	1	00730	
	1	01825	
	28	88888 Blank but applicable	
	20016	Blank	
564-567 HAX9DV		Primary drug class code (16th medication reported)	See note
	1	0348	
	28	8888 Blank but applicable	
	20021	Blank	
568-571 HAX9EV		Secondary drug class code (16th medication reported)	See note
	29	8888 Blank but applicable	
	20021	Blank	
572-575 HAX9FV		Tertiary drug class code (16th medication reported)	See note
	29	8888 Blank but applicable	
	20021	Blank	
576-581 HAX11AV		ICD-9-CM code (16th medication reported)	See note
	1	692.9	
	28	888888 Blank but applicable	
	20021	Blank	
582-586 HAX12SV		For how long have you been taking or using (MEDICINE)? (days) (16th medication reported)	See note
	1	02190	
	28	88888 Blank but applicable	
	20021	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
		Antacids	
587-589 HAX13AG		Antacid identification code (1st antacid reported)	See note
	3826	100-459	
	108	888 Blank but applicable	
	16	999 Don't know	
	16100	Blank	
590-593 HAX15SG		How often did you take (ANTACID) in the past month? (1st antacid reported)	See note
	3793	0001-0608	
	133	8888 Blank but applicable	
	24	9999 Don't know	
	16100	Blank	
594-595 HAX16AG		How much (ANTACID) did you take each time you took it? (quantity) (1st antacid reported)	See note
	1722	01	
	1751	02	
	131	03	
	65	04	
	11	05	
	11	06	
	1	07	
	2	08	
	2	10	
	1	30	
	248	88 Blank but applicable	
	5	99 Don't know	
	16100	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
596-597 HAX16A1G		How much (ANTACID) did you take each time you took it? (unit) (1st antacid reported)	See note
	2601	01 Tablets or pills	
	312	02 Teaspoons	
	747	03 Tablespoons	
	25	04 Fluid ounces	
	7	05 Pieces of gum	
	5	06 Envelopes or packets	
	248	88 Blank but applicable	
	5	99 Don't know	
	16100	Blank	
598-601 HAX17SG		For how long have you been taking this antacid? (months) (1st antacid reported)	See note
	3491	0001-0936	
	195	7777 Used less than one month	
	108	8888 Blank but applicable	
	156	9999 Don't know	
	16100	Blank	
602-604 HAX13AH		Antacid identification code (2nd antacid reported)	See note
	377	110-459	
	87	888 Blank but applicable	
	2	999 Don't know	
	19584	Blank	
605-608 HAX15SH		How often did you take (ANTACID) in the past month? (2nd antacid reported)	See note
	369	0001-0213	
	91	8888 Blank but applicable	
	6	9999 Don't know	
	19584	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
609-610 HAX16AH		How much (ANTACID) did you take each time you took it? (quantity) (2nd antacid reported)	See note
	145	01	
	186	02	
	12	03	
	8	04	
	1	06	
	1	10	
	108	88 Blank but applicable	
	5	99 Don't know	
	19584	Blank	
611-612 HAX16A1H		How much (ANTACID) did you take each time you took it? (unit) (2nd antacid reported)	See note
	232	01 Tablets or pills	
	32	02 Teaspoons	
	80	03 Tablespoons	
	4	04 Fluid ounces	
	3	05 Pieces of gum	
	2	06 Envelopes or packets	
	108	88 Blank but applicable	
	5	99 Don't know	
	19584	Blank	
613-616 HAX17SH		For how long have you been taking this antacid? (months) (2nd antacid reported)	See note
	341	0001-0480	
	10	7777 Used less than one month	
	95	8888 Blank but applicable	
	20	9999 Don't know	
	19584	Blank	
617-619 HAX13AI		Antacid identification code (3rd antacid reported)	See note
	37	119-459	
	85	888 Blank but applicable	
	19928	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
620-623 HAX15SI		How often did you take (ANTACID) in the past month? (3rd antacid reported)	See note
	33	0001-0091	
	87	8888 Blank but applicable	
	2	9999 Don't know	
	19928	Blank	
624-625 HAX16AI		How much (ANTACID) did you take each time you took it? (quantity) (3rd antacid reported)	See note
	14	01	
	20	02	
	87	88 Blank but applicable	
	1	99 Don't know	
	19928	Blank	
626-627 HAX16A1I		How much (ANTACID) did you take each time you took it? (unit) (3rd antacid reported)	See note
	23	01 Tablets or pills	
	1	02 Teaspoons	
	10	03 Tablespoons	
	87	88 Blank but applicable	
	1	99 Don't know	
	19928	Blank	
628-631 HAX17SI		For how long have you been taking this antacid? (months) (3rd antacid reported)	See note
	32	0002-0600	
	86	8888 Blank but applicable	
	4	9999 Don't know	
	19928	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
632-634 HAX13AJ		Antacid identification code (4th antacid reported)	See note
	2	309	
	1	330	
	1	350	
	1	399	
	85	888 Blank but applicable	
	19960	Blank	
635-638 HAX15SJ		How often did you take (ANTACID) in the past month? (4th antacid reported)	See note
	1	0001	
	1	0003	
	1	0009	
	1	0010	
	1	0013	
	85	8888 Blank but applicable	
	19960	Blank	
639-640 HAX16AJ		How much (ANTACID) did you take each time you took it? (quantity) (4th antacid reported)	See note
	3	01	
	1	02	
	86	88 Blank but applicable	
	19960	Blank	
641-642 HAX16A1J		How much (ANTACID) did you take each time you took it? (unit) (4th antacid reported)	See note
	2	01 Tablets or pills	
	1	03 Tablespoons	
	1	04 Fluid ounces	
	86	88 Blank but applicable	
	19960	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
643-646 HAX17SJ		For how long have you been taking this antacid? (months) (4th antacid reported)	See note
	1	0024	
	1	0120	
	1	0180	
	1	0240	
	85	8888 Blank but applicable	
	1	9999 Don't know	
	19960	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
		Next are questions about non-prescription pain relief medicines.	
647 HAX18A		In the past month, have you taken any aspirin, Anacin, Bufferin, Ecotrin, Ascriptin, or Midol?	
	6518	1 Yes	
	13386	2 No	
	100	8 Blank but applicable	
	46	9 Don't know	
648-650 HAX19AS		How often did you take aspirin, Anacin, Bufferin, Ecotrin, Ascriptin, or Midol during the past month?	See note
	6388	001-547	
	211	888 Blank but applicable	
	19	999 Don't know	
	13432	Blank	
651 HAX18B		In the past month, have you taken any Tylenol, Anacin-3, or acetaminophen?	
	7317	1 Yes	
	12596	2 No	
	91	8 Blank but applicable	
	46	9 Don't know	
652-654 HAX19BS		How often did you take Tylenol, Anacin-3, or acetaminophen during the past month?	See note
	7226	001-638	
	150	888 Blank but applicable	
	32	999 Don't know	
	12642	Blank	
655 HAX18C		In the past month, have you taken any Advil, Nuprin, Medipren, or ibuprofen?	
	3673	1 Yes	
	16231	2 No	
	94	8 Blank but applicable	
	52	9 Don't know	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
656-658 HAX19CS		How often did you take Advil, Nuprin, Medipren, or ibuprofen during the past month?	See note
	3652	001-365	
	107	888 Blank but applicable	
	8	999 Don't know	
	16283	Blank	
659 HAX18D		In the past month, have you taken any other pain relief medicines? (1st other pain relief medicine reported)	See note
	1118	1 Yes	
	18659	2 No	
	222	8 Blank but applicable	
	51	9 Don't know	
660-661 HAX18DB		Product type (1st other pain relief medicine reported)	See note
	315	01 Other ingested pain medications	
	13	02 Topical pain relief medications	
	274	03 Cold, cough, flu, sinus or allergy medications with pain reliever(s)	
	317	04 Other cold, cough, flu, sinus or allergy medications	
	90	05 Laxatives or stool softeners	
	9	06 Diarrhea medications	
	8	07 Sleep aids	
	72	08 Other medications	
	242	88 Blank but applicable	
	18710	Blank	
662-664 HAX19DS		How often have you taken (OTHER PAIN RELIEF MEDICINE) during the past month? (1st other pain relief medicine reported)	See note
	967	001-213	
	371	888 Blank but applicable	
	2	999 Don't know	
	18710	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
665 HAX18E		In the past month, have you taken any other pain relief medicines? (2nd other pain relief medicine reported)	See note
	95	1 Yes	
	847	2 No	
	174	8 Blank but applicable	
	2	9 Don't know	
	18932	Blank	
666-667 HAX18EB		Product type (2nd other pain relief medicine reported)	See note
	6	01 Other ingested pain medications	
	2	02 Topical pain relief medications	
	35	03 Cold, cough, flu, sinus or allergy medications with pain reliever(s)	
	37	04 Other cold, cough, flu, sinus or allergy medications	
	7	05 Laxatives or stool softeners	
	1	06 Diarrhea medications	
	1	07 Sleep aids	
	5	08 Other medications	
	1	12	
	174	88 Blank but applicable	
	19781	Blank	
668-670 HAX19ES		How often have you taken (OTHER PAIN RELIEF MEDICINE) during the past month? (2nd other pain relief medicine reported)	See note
	82	001-061	
	187	888 Blank but applicable	
	19781	Blank	
671 HAX18F		In the past month, have you taken any other pain relief medicines? (3rd other pain relief medicine reported)	See note
	17	1 Yes	
	65	2 No	
	12	8 Blank but applicable	
	1	9 Don't know	
	19955	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
672-673 HAX18FB		Product type (3rd other pain relief medicine reported)	See note
	2	02 Topical pain relief medications	
	5	03 Cold, cough, flu, sinus or allergy medications with pain reliever(s)	
	6	04 Other cold, cough, flu, sinus or allergy medications	
	4	05 Laxatives or stool softeners	
	12	88 Blank but applicable	
	20021	Blank	
674-676 HAX19FS		How often have you taken (OTHER PAIN RELIEF MEDICINE) during the past month? (3rd other pain relief medicine reported)	See note
	2	002	
	2	003	
	2	004	
	2	005	
	1	006	
	1	008	
	1	013	
	1	030	
	1	061	
	1	091	
	15	888 Blank but applicable	
	20021	Blank	
677 HAX18G		In the past month, have you taken any other pain relief medicines? (4th other pain relief medicine reported)	See note
	4	1 Yes	
	11	2 No	
	2	8 Blank but applicable	
	20033	Blank	

NHANES III Partial Household Adult Data File

HOUSEHOLD ADULT QUESTIONNAIRE (HAQ)

GENERAL INFORMATION

Positions SAS name	Counts	Item description and code	Notes
678-679 HAX18GB		Product type (4th other pain relief medicine reported)	See note
	1	02 Topical pain relief medications	
	1	04 Other cold, cough, flu, sinus or allergy medications	
	2	08 Other medications	
	2	88 Blank but applicable	
	20044	Blank	
680-682 HAX19GS		How often have you taken (OTHER PAIN RELIEF MEDICINE) during the past month? (4th other pain relief medicine reported)	See note
	1	004	
	1	122	
	4	888 Blank but applicable	
	20044	Blank	

Special Notes:

HAX1A: Have you taken any vitamins or minerals in the past month?

This variable is the response to a lead-in question for a series of questions on vitamins and mineral supplements. If the response was yes, then respondents were asked the number of supplements they took. For each supplement taken respondents were asked about how often the supplement was taken, the dosage, and duration of use. Analysts should be aware, however, that there were respondents who reported taking supplements, but did not answer some or all of the remaining questions about the supplements. Although the lead-in question was designed to determine whether respondents were using any vitamin or mineral supplements, respondents often reported taking other types of dietary supplements such as formula diets, sports drinks, herbs, products, amino acids, bee pollen, lipotropics, fish oils, and enzymes. This information was retained along with the vitamin/mineral supplements. However, since there were not probes for use of other vitamin/nonmineral dietary supplements, the frequency with which these products were reported can not be considered nationally representative. It should also be noted that all of the information from the section does not appear in this data file; additional variables including supplement formulations will be released as a separate data file.

HAX1B: Have you taken or used any prescription medicines in the past month?

This variable is the response to a lead-in question for a series of questions on prescription medicines. If the response was yes, then the respondents were asked the number of prescription medicines they took. For each prescription medicine the respondent was asked to describe the health problem for which they took the medicine, and how long they had been taking the medicine. Analysts should be aware, however, that there were respondents who reported taking prescription medicines, but were only able to answer some of the remaining prescription drug questions. Prescribed vitamin or mineral supplements (e.g., fluoride, iron, and prenatal vitamins) originally reported as prescription drugs were moved to the vitamin/mineral section. These could, in fact, be considered either a drug or a supplement (e.g. such as calcium-based antacid, calcitrol, and potassium. It should also be noted that all of the information from the section does not appear in this data file; additional variables including drug formulations will be released as a separate data file.

HAX1C: Have you taken antacids in the past month?

This variable is the response to a lead-in question for a series of questions on antacid use. If the response was yes, respondents were asked the number of antacids they took. For each antacid, respondents were asked how often it was taken, the dosage, and the duration of use. Antacids listed here are only those purchased over-the-counter. Prescription antacids were moved to the prescription medication section (HAX9-HAX12 variables). Some of these products are currently available without a prescription (e.g. "Zantac") but were available only by prescription at the time that the data were collected.

HAX2A: Number of vitamins or mineral supplements reported

This variable represents the total number of different supplements reported by the respondent. For each supplement, the interviewer asked to see the supplement container in order to record the name of the product and the manufacturer. If the container was not available, the interviewer probed for this information. Supplements that appear to be identical or duplications of another reported product are usually different forms (e.g., tablet vs. liquid) of the same product.

HAX2B: Number of prescription medicines reported

This variable represents the total number of different prescription medicines reported by the respondent. For each medication reported, the interviewer asked to see the medication container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Reports of non-prescription drug use were deleted, or moved (as in the case of calcium-containing antacids). Medicines that appear to be identical or duplications of another reported product are usually different forms (e.g., tablet vs. liquid) of the same product.

HAX2C: Number of antacids reported

This variable represents the total number of different antacids reported by the respondent or proxy. For each antacid reported, the interviewer asked to see the container in order to record the name of the product. If the container was not available, the interviewer probed for this information.

HAX3CG, HAX3CH, HAX3CI, HAX3CJ, HAX3CK, HAX3CL, HAX3CM, HAX3CN, HAX3CO, HAX3CP, HAX3CQ, HAX3CR, HAX3CS, HAX3CT, HAX3CU, HAX3CV, HAX3CW :
Certainty index codes for vitamin and mineral supplements

A certainty index was derived as a means of evaluating how closely the reported name of a dietary supplement matched a standard or brand name product which, in turn, was used for determining nutrient intakes. Each reported dietary supplement was assigned a certainty code. The index consists of six levels ranging from the highest degree of certainty that the reported supplement was correctly identified (code=1) to no level the lowest degree of certainty (code=6) , i.e., no match could be made between the reported supplement and a standard supplement. More specifically, the code of 1 was used when the respondent provided enough information about the product that it exactly matched a specific brand name supplement. A code of 2 was applied when the product name was partially incomplete or misspelled, but generally identifiable. A code of 3 was used for cases where a single nutrient supplement, such as calcium, was reported without the concentration. A code of 4 was applied when a generic type of supplement was reported such as "children's chewable multivitamins" or "iron vitamins" when it was not

possible to identify the specific brand name or nutrient composition. A code of 5 was assigned to supplements that could not be readily identified although they were thought to be dietary supplements such as "Shaklee vitamins" or "Diamite nutritional". A code of 6 was used for products that could not be identified but were assumed to be a dietary supplement.

HAX3DG, HAX3DH, HAX3DI, HAX3DJ, HAX3DK, HAX3DL, HAX3DM, HAX3DN, HAX3DO,
HAX3DP, HAX3DQ, HAX3DR, HAX3DS, HAX3DT, HAX3DU, HAX3DV, HAX3DW:
Product class for vitamin and mineral supplements

Each reported dietary supplement was categorized into one of 7 broad product-type classes according to general nutrient composition. The first five classes (1-5) were assigned only to vitamin and/or mineral supplements. The remaining two classes (6 and 7) were assigned to other dietary supplements including amino acids, lipotropics, herbs, plants and other nontraditional dietary supplements. Dietary supplements that also contained a vitamin and/or a mineral (e.g., ginseng and bee pollen with vitamin E) were assigned to class 6, whereas those that did not include vitamins or minerals were assigned to class 7.

HAX6SG, HAX6SH, HAX6SI, HAX6SJ, HAX6SK, HAX6SL, HAX6SM, HAX6SN, HAX6SO,
HAX6SP, HAX6SQ, HAX6SR, HAX6ST, HAX6SU, HAX6SV, HAX6SW
How often did you take supplement in the past month?

These variables were created for each reported dietary supplement from the two-part (number and unit) question X6, and indicate how frequently each supplement was taken in the past month. The conversion factors used for days and weeks were 30 and 4, respectively. While frequency of use was standardized to "month," new supplement users may have been taking the supplement for less than a month at the time of the interview. Analysts, therefore, may want to examine duration (HAX8S variables) as well as frequency of use.

HAX8SG, HAX8SH, HAX8SI, HAX8SJ, HAX8SK, HAX8SL, HAX8SM, HAX8SN, HAX8SO,
HAX8SP, HAX8SQ, HAX8SR, HAX8SS, HAX8ST, HAX8SU, HAX8SV, HAX8SW:
How long have you been taking this product? (months)

This variable was created from the two-part (number and unit) question X8, and indicates the long-term duration of use. The conversion factor was 12 months/year. When supplements were reported as prescription drugs and then moved as part of the data editing process (see note for variable HAX1A) much of the information was not directly transferable. For example, categories for duration of taking drugs (HAX12S variables) did not always match those listed for the corresponding question for vitamin/mineral supplements (HAX8S variables). Responses reported in weeks were rounded to the nearest month, whereas response in months and years were transferred directly.

HAX9DG, HAX9DH, HAX9DI, HAX9DJ, HAX9DK, HAX9DL, HAX9DM, HAX9DN, HAX9DO:
HAX9DP, HAX9DQ, HAX9DR, HAX9DS, HAX9DT, HAX9DU, HAX9DV:
Primary drug class code

Up to three drug class codes were assigned for each reported prescription medication. These 4-digit codes were supplied by the Product Information Branch, Center for Drug Evaluation and Research at the U.S. DDHS Food and Drug Administration. The version of these codes that was used was last updated in October 1994. The primary drug class code assignment was based on the known drug action. For example, all cardiovascular drugs that were beta-adrenergic blocking agents were assigned the drug class code 0512 (beta blockers). See Appendix 3 for listing of codes.

HAX9EG, HAX9EH, HAX9EI, HAX9EJ, HAX9EK, HAX9EL, HAX9EM, HAX9EN, HAX9EO,
HAX9EP, HAX9EQ, HAX9ER, HAX9ES, HAX9ET, HAX9EU, HAX9EV:
Secondary drug class code

This variable contains the second drug class codes for each prescription drug reported. If the medical condition for which the medication was used (as reported in question X11) was different than the known drug action, then a secondary drug class code was entered. For example, a cardiovascular drug that was a beta-adrenergic blocking agent was assigned the drug class code 0512 (beta blocker) as the primary drug code, and a secondary drug class of 0502 (antiarrhythmic). If the reason provided did not relate to any of the known actions of the drug, then only the medication-specific (primary) class code was assigned. See Appendix 3 for listing of codes.

HAX9FG, HAX9FH, HAX9FI, HAX9FJ, HAX9FK, HAX9FL, HAX9FM, HAX9FN, HAX9FO,
HAX9FP, HAX9FQ, HAX9FR, HAX9FS, HAX9FT, HAX9FU, HAX9FV:
Tertiary drug class code

This variable contains the tertiary drug class codes for each prescription drug reported. If the medical condition for which the medication was used (as reported in question X11) was different than the primary drug class, then a secondary, and tertiary drug class code was entered. For example, a cardiovascular drug was assigned the drug class code 0512 (beta blocker) as the primary drug code, a secondary drug class code of 0502 (antiarrhythmics), and a tertiary code of 0506 (antihypertensives). If the reason provided did not relate to any of the actions of the drug, then only the medication-specific class code (primary) was assigned. See Appendix 3 for listing of codes.

HAX11AG, HAX11AH, HAX11AI, HAX11AJ, HAX11AK, HAX11AL, HAX11AM, HAX11AN,
HAX11AO, HAX11AP, HAX11AQ, HAX11AR, HAX11AS, HAX11AT, HAX11AU, HAX11AV:
ICD-9-CM code for prescription medicine

ICD-9-CM codes were used to classify the medical conditions reported in question X11 for each prescription drug reported. Conditions were coded to the fourth digit ICD-9-CM level of specificity except in those cases where the three digit ICD-9-CM code is the highest level of specificity. Some conditions where no appropriate code was available in the Classification of Diseases and Injuries ICD-9-CM codes, were coded using V Codes - Supplementary Classification of factors Influencing Health Status and Contact with Health Services. See Appendix 4 for listing of

codes.

HAX12SG, HAX12SH, HAX12SI, HAX12SJ, HAX12SK, HAX12SL, HAX12SM, HAX12SN,
HAX12SP, HAX12SQ, HAX12SR, HAX12SS, HAX12ST, HAX12SU, HAX12SV:

For how long have you been taking this medicine? (days)

This variable was created from the two-part (number and unit) question X12 using the conversion factors 7 days/week, 30 days/month and 365 days/year. Duration could not always be directly transferred for medicines originally reported as supplements and moved in the data editing process. This was because the duration response categories for supplement use (X8) did not match the corresponding response categories for prescription medicines (X12). A response of "less than one month" in X8 was changed to blank but applicable (8-fills) in X12 for medicines that were originally recorded as supplements.

HAX13AG, HAX13AH, HAX13AI, HAX13AJ: Antacid identification code

This variable was created to identify over-the-counter antacids. The coding scheme enabled responses to be classified at various levels of specificity, depending on the information provided by the respondent. The codes are for specific products, as well for incomplete trade names or more general responses. As necessary, data from the unit of measure question (X16) were used to aid in coding antacid responses. For example, Pepto Bismol is available in two liquid forms of the product (350 or 351), and in the tablet form (352). If the unit of measure specified tablets or pills then the product was coded as Pepto Bismol Tablets (352). Responses that were likely to be antacids but could not be further identified, and generic antacid products were all coded as "other antacids" (459).

HAX15SG, HAX15SH, HAX15SI, HAX15SJ: How often did you take this antacid in the past month?

This variable was created for each reported antacid from the two-part (number and unit) question X15, using the conversion factors used 30 days/month and 4 weeks/month.

HAX16AG, HAX16AH, HAX16AI, HAX16AJ: How much did you take of this antacid each time? (quantity)

This variable is the first part of a two-part question (X16) on the dosage for each reported antacid. It lists the amount taken. Amounts that were reported in ways that could not be measured, such as "as necessary" or "PRN", were 8-filled.

HAX16A1G, HAX16A1H, HAX16A1I, HAX16A1J: How much did you take of this antacid each time? (unit)

This variable is the second part of a two-part question (X16) on the dosage of the antacid taken. It lists the unit for the quantity reported for each antacid reported.

HAX17SG, HAX17SH, HAX17SI, HAX17SJ: How long have you been taking this antacid? (months)

This variable was created from the two-part (number and unit) question X17 using the conversion factors used were 30 days/month, 4 weeks/month, and 12 months/year. Responses of 5 and 6 weeks, or 10 weeks were rounded to one and two months, respectively.

HAX18D, HAX18E, HAX18F, HAX18G: Have you taken any other pain relief medicines in the past month?

Respondents were asked about other non-prescription pain relief medicines reported, other than aspirin, acetaminophen, and ibuprofen.

HAX18DB, HAX18EB, HAX18FB, HAX18GB: Product type code for other pain relief medicines

A product type code was created to classify pain relievers that were not aspirin, acetaminophen, and ibuprofen. Combinations of aspirin and acetaminophen (e.g. "Excedrin Extra Strength Tablets") were categorized as "Other ingested pain medications" (1). However, combinations of aspirin and caffeine (e.g. "Anacin"), and aspirin with a buffering agent (e.g. "Bufferin") were considered aspirin and moved to X18a. Pain relievers that were known to be available only by prescription (e.g. "Darvon") were moved to the prescription medication section (X9-X12). When reported in this section, "Alka Seltzer" was treated as a non-prescription pain relief medication since it was assumed that if it was reported here it was being used for pain relief.

HAX19AS: How often did you take aspirin in the past month?

This variable was created from the two-part (number and unit) question X19a using the conversion factors 30 days/month and 4 weeks/months.

HAX19BS: How often did you take acetaminophen in the past month?

This variable was created from the two-part (number and unit) question X19b using the conversion factors 30 days/month and 4 weeks/months.

HAX19CS: How often did you take ibuprofen in the past month?

This variable was created from the two-part (number and unit) question X19c using the conversion factors 30 days/month and 4 weeks/months.

HAX19DS, HAX19ES, HAX19FS, HAX19GS: How often did you take other pain relief medicine in the past month?

This variable was created from the two-part (number and unit) question X19 using the conversion factors 30 days/week and 4 weeks/month.

Appendix 1

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0002	ACEBUTOLOL HYDROCHLORIDE
0020	ACETAMINOPHEN; BUTALBITAL
0021	ACETAMINOPHEN; BUTALBITAL; CAFFEINE
0022	ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0046	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0048	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE
0050	ACETAMINOPHEN; CHLORZOXAZONE
0051	ACETAMINOPHEN; CODEINE PHOSPHATE
0064	ACETAMINOPHEN; DICHLORALPHENAZONE; ISOMETHEPTENE MUCATE
0070	ACETAMINOPHEN; HYDROCODONE BITARTRATE
0072	ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
0074	ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
0081	ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
0082	ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
0084	ACETAMINOPHEN; SALICYLAMIDE
0086	ACETAZOLAMIDE
0087	ACETIC ACID

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0088	ACETIC ACID; HYDROCORTISONE
0092	ACETOHEXAMIDE

0105	ACYCLOVIR
0115	ALBUTEROL
0116	ALCLOMETASONE DIPROPIONATE
0133	ALLOPURINOL
0140	ALPRAZOLAM
0154	ALUMINUM CHLORIDE HEXAHYDRATE
0174	AMANTADINE HYDROCHLORIDE
0176	AMCINONIDE
0179	AMILORIDE HYDROCHLORIDE
0180	AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
0207	AMINOPHYLLINE
0212	AMIODARONE HYDROCHLORIDE
0213	AMITRIPTYLINE HYDROCHLORIDE
0214	AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE
0215	AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
0230	AMOXAPINE
0231	AMOXICILLIN
0232	AMOXICILLIN; CLAVULANATE POTASSIUM
0239	AMPICILLIN/AMPICILLIN TRIHYDRATE
0244	AMYLASE; CELLULASE; LIPASE; PROTEASE
0254	ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
0255	ANTHRALIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0260	ANTIHEMOPHILIC FACTOR, HUMAN
0263	ANTIPYRINE; BENZOCAINE
0264	ANTIPYRINE; BENZOCAINE;

	PHENYLEPHRINE HYDROCHLORIDE
0276	APRACLONIDINE HYDROCHLORIDE
0299	ASPIRIN
0302	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0304	ASPIRIN; BUTALBITAL; CAFFEINE
0306	ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
0310	ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
0311	ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
0314	ASPIRIN; CARISOPRODOL
0315	ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
0317	ASPIRIN; CODEINE PHOSPHATE
0320	ASPIRIN; MEPROBAMATE
0321	ASPIRIN; METHOCARBAMOL
0322	ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
0332	ASTEMIZOLE
0333	ATENOLOL
0334	ATENOLOL; CHLORTHALIDONE
0336	ATROPINE SULFATE
0338	ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
0339	ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
0340	ATROPINE SULFATE; BENZOIC ACID; HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0347	AURANOFIN
0349	AZATADINE MALEATE
0350	AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
0351	AZATHIOPRINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0356	BACITRACIN
0357	BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
0358	BACITRACIN ZINC; POLYMYXIN B SULFATE
0361	BACLOFEN
0376	BECLOMETHASONE DIPROPIONATE
0380	BELLADONNA; CAFFEINE; ERGOTAMINE; PENTOBARBITAL
0382	BELLADONNA
0383	BELLADONNA ALKALOIDS; PHENOBARBITAL
0389	BELLADONNA; ENZYME(S); PHENOBARBITAL
0391	BELLADONNA; KAOLIN; PAREGORIC; PECTIN
0403	BENDROFLUMETHIAZIDE; NADOLOL
0417	BENZOCAINE
0446	BENZONATATE
0447	BENZOYL PEROXIDE
0448	BENZOYL PEROXIDE; ERYTHROMYCIN
0455	BENZTROPINE MESYLATE
0462	BETAMETHASONE
0465	BETAMETHASONE DIPROPIONATE
0466	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
0468	BETAMETHASONE VALERATE
0469	BETAXOLOL HYDROCHLORIDE
0470	BETHANECHOL CHLORIDE
0476	BILE SALTS; PANCREATIN; PEPSIN
0505	BITOLTEROL MESYLATE
0527	BROMOCRIPTINE MESYLATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0528	BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
0529	BROMPHENIRAMINE MALEATE
0530	BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0531	BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
0532	BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0533	BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0534	BROMPHENIRAMINE; DEXTROMETHORPHAN; PHENYLPROPANOLAMINE
0538	BROMPHENIRAMINE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLTOLOXAMINE
0544	BUMETANIDE
0550	BUPROPION HYDROCHLORIDE
0551	BUSPIRONE HYDROCHLORIDE
0557	BUTABARBITAL SODIUM
0574	CAFFEINE; ERGOTAMINE TARTRATE
0585	CALCITONIN, SALMON
0586	CALCITRIOL
0607	CALCIUM IODIDE; CODEINE PHOSPHATE
0642	CAPTOPRIL
0643	CAPTOPRIL; HYDROCHLOROTHIAZIDE
0644	CARAMIPHEN; PHENYLPROPANOLAMINE
0645	CARBACHOL
0646	CARBAMAZEPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0652	CARBETAPENTANE TANNATE; CHLORPHENIRAMINE TANNATE; EPHEDRINE TANNATE; PHENYLEPHRINE HYDROCHLORIDE
0653	CARBIDOPA; LEVODOPA
0655	CARBINOXAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
0656	CARBINOXAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0664	CARISOPRODOL
0666	CARTEOLOL HYDROCHLORIDE
0680	CEFACLOR
0681	CEFADROXIL
0684	CEFIXIME
0687	CEFOPERAZONE SODIUM
0694	CEFTRIAZONE SODIUM
0695	CEFUROXIME AXETIL
0698	CEPHALEXIN
0699	CEPHALEXIN HYDROCHLORIDE
0702	CEPHRADINE
0726	CHLORDIAZEPOXIDE HYDROCHLORIDE
0727	CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE
0728	CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED
0729	CHLORHEXIDINE GLUCONATE
0738	CHLOROQUINE PHOSPHATE
0739	CHLOROTHIAZIDE
0740	CHLOROTHIAZIDE; METHYLDOPA
0741	CHLOROTHIAZIDE; RESERPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0743	CHLOROXINE
0749	CHLORPHENIRAMINE MALEATE; HYDROCODONE; PHENYLEPHRINE HYDROCHLORIDE
0751	CHLORPHENIRAMINE MALEATE
0753	CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0754	CHLORPHENIRAMINE MALEATE; EPINEPHRINE
0755	CHLORPHENIRAMINE MALEATE; METHSCOPOLAMINE NITRATE; PHENYLEPHRINE HYDROCHLORIDE
0756	CHLORPHENIRAMINE MALEATE; PHENINDAMINE TARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0757	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLTOLOXAMINE CITRATE
0758	CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0759	CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0760	CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
0761	CHLORPHENIRAMINE TANNATE; PHENYLEPHRINE TANNATE; PYRILAMINE TANNATE
0767	CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; POTASSIUM IODIDE
0775	CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
0776	BECLOMETHASONE DIPROPIONATE
0790	CHLORPHENIRAMINE MALEATE; HYDROCODONE; PSEUDOEPHEDRINE
0792	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0793	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PYRILAMINE
0797	CHLORPROMAZINE HYDROCHLORIDE
0798	CHLORPROPAMIDE
0801	CHLORTHALIDONE
0802	CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
0803	CHLORTHALIDONE; RESERPINE
0804	CHLORZOXAZONE
0808	CHOLESTYRAMINE
0811	CHOLINE MAGNESIUM TRISALICYLATE
0817	CICLOPIROX OLAMINE
0820	CIMETIDINE
0823	CIPROFLOXACIN HYDROCHLORIDE
0830	CITRIC ACID; SODIUM CITRATE
0835	CLEMASTINE FUMARATE
0836	CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0838	CLINDAMYCIN HYDROCHLORIDE
0839	CLOBETASOL PROPIONATE
0842	CLOFIBRATE
0843	CLOMIPHENE CITRATE
0845	CLONAZEPAM
0846	CLONIDINE HYDROCHLORIDE
0847	CLORAZEPATE DIPOTASSIUM
0848	CLOTRIMAZOLE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0850	CLOXACILLIN SODIUM
0851	CLOZAPINE
0870	CODEINE PHOSPHATE
0873	CODEINE PHOSPHATE; GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
0874	CODEINE PHOSPHATE; IODINATED GLYCEROL
0875	CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
0876	CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
0878	CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
0881	CODEINE PHOSPHATE; GUAIFENESIN
0883	CODEINE PHOSPHATE; GUAIFENESIN; PHENYLPROPANOLAMINE
0890	COLCHICINE
0891	COLCHICINE; PROBENECID
0892	COLESTIPOL HYDROCHLORIDE
0894	COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
0907	CORTISONE ACETATE
0916	CROMOLYN SODIUM
0924	CYCLANDELATE
0926	CYCLOBENZAPRINE HYDROCHLORIDE
0930	CYCLOPHOSPHAMIDE
0932	CYCLOSPORINE
0934	CYPROHEPTADINE HYDROCHLORIDE
0940	DANAZOL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0944	DANTROLENE SODIUM
0947	DEFEROXAMINE MESYLATE
0951	DEHYDROCHOLIC ACID
0963	DESERPIDINE; METHYCLOTHIAZIDE
0964	DESIPRAMINE HYDROCHLORIDE
0966	DESMOPRESSIN ACETATE
0967	DESONIDE
0968	DESOXIMETASONE
0974	DEXAMETHASONE
0976	DEXAMETHASONE SODIUM PHOSPHATE
0978	DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
0979	DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
0980	DEXAMETHASONE; TOBRAMYCIN
0982	DEXBROMPHENIRAMINE; PSEUDOEPHEDRINE
0983	DEXCHLORPHENIRAMINE MALEATE
0987	DEXTRAN
0992	DEXTROAMPHETAMINE SULFATE
0994	DEXTROMETHORPHAN HYDROBROMIDE; IODINATED GLYCEROL
0995	DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
1000	DEXTROMETHORPHAN; GUAIFENESIN
1033	DIAZEPAM
1044	DICHLORPHENAMIDE
1045	DICLOFENAC SODIUM
1046	DICLOXACILLIN SODIUM

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1048	DICYCLOMINE HYDROCHLORIDE
1050	DIENESTROL
1053	DIETHYLPROPION HYDROCHLORIDE
1054	DIETHYLSTILBESTROL
1055	DIETHYLSTILBESTROL DIPHOSPHATE
1057	DIFLORASONE DIACETATE
1058	DIFLUNISAL
1060	DIGITOXIN
1061	DIGOXIN
1063	DIHYDROERGOTAMINE MESYLATE
1065	DIHYDROTACHYSTEROL
1068	HYDROCORTISONE; IODOQUINOL
1069	DILTIAZEM HYDROCHLORIDE
1070	DIMENHYDRINATE
1079	DIPHENHYDRAMINE HYDROCHLORIDE
1088	DIPIVEFRIN HYDROCHLORIDE
1090	DIPYRIDAMOLE
1093	DISOPYRAMIDE PHOSPHATE
1096	DIVALPROEX SODIUM
1111	DOXEPIN HYDROCHLORIDE
1113	DOXYCYCLINE
1122	DYPHYLLINE
1124	DYPHYLLINE; GUAIFENESIN
1126	ECHOTHIOPHATE IODIDE
1127	ECONAZOLE NITRATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1138	ENALAPRIL MALEATE
1139	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
1141	ENCAINIDE HYDROCHLORIDE
1145	ENZYME(S); HYOSCYAMINE SULFATE; PHENYLTOLOXAMINE CITRATE
1149	EPHEDRINE
1151	EPHEDRINE HYDROCHLORIDE; PHENOBARBITAL; THEOPHYLLINE ANHYDROUS
1152	EPHEDRINE SULFATE; HYDROXYZINE HYDROCHLORIDE; THEOPHYLLINE
1160	EPHEDRINE HYDROCHLORIDE; POTASSIUM IODIDE; PHENOBARBITAL; THEOPHYLLINE
1166	EPINEPHRINE
1169	EPINEPHRYL BORATE
1172	EPINEPHRINE; PILOCARPINE
1173	EPOETIN ALFA
1174	ERGOCALCIFEROL
1175	ERGOLOID MESYLATES
1177	ERGOTAMINE TARTRATE
1178	ERYTHRITYL TETRANITRATE
1179	ERYTHROMYCIN
1180	ERYTHROMYCIN ESTOLATE
1181	ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL
1182	ERYTHROMYCIN ETHYLSUCCINATE
1184	ERYTHROMYCIN LACTOBIONATE
1185	ERYTHROMYCIN STEARATE
1188	ESTRADIOL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1191	ESTRADIOL VALERATE
1195	ESTRAMUSTINE PHOSPHATE SODIUM
1196	ESTROGENIC SUBSTANCES
1197	ESTROGENS, CONJUGATED
1200	ESTROGENS, ESTERIFIED
1201	ESTROGENS, ESTERIFIED; METHYLTESTOSTERONE
1204	ESTROPIPATE
1206	ETHAMBUTOL HYDROCHLORIDE
1208	ETHAVERINE HYDROCHLORIDE
1213	ETHCHLORVYNOL
1216	ETHINYL ESTRADIOL
1217	ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
1219	ETHINYL ESTRADIOL; LEVONORGESTREL
1220	ETHINYL ESTRADIOL; NORETHINDRONE
1221	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE; FERROUS FUMARATE
1222	ETHINYL ESTRADIOL; NORGESTREL
1226	ETHOSUXIMIDE
1234	ETIDRONATE DISODIUM
1237	ETRETINATE
1246	FAMOTIDINE
1253	FENOPROFEN CALCIUM
1297	FLAVOXATE HYDROCHLORIDE
1299	FLECAINIDE ACETATE
1301	FLUCONAZOLE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1303	FLUDROCORTISONE ACETATE
1305	FLUNISOLIDE
1306	FLUOCINOLONE ACETONIDE
1310	FLUOCINONIDE
1317	FLUROMETHOLONE
1319	FLUOROURACIL
1320	FLUOXETINE HYDROCHLORIDE
1321	FLUOXYMESTERONE
1322	FLUPHENAZINE DECANOATE
1324	FLUPHENAZINE HYDROCHLORIDE
1325	FLURANDRENOLIDE
1327	FLURAZEPAM HYDROCHLORIDE
1328	FLURBIPROFEN
1330	FLUTAMIDE
1331	FOLIC ACID
1342	FUROSEMIDE
1351	GEMFIBROZIL
1352	GENTAMICIN SULFATE
1353	GENTAMICIN SULFATE; PREDNISOLONE ACETATE
1357	GLIPIZIDE
1366	GLUTETHIMIDE
1368	GLYBURIDE
1377	GLYCOPYRROLATE
1379	GOLD SODIUM THIOMALATE
1382	GOSERELIN ACETATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1385	GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1388	GRISEOFULVIN, MICROCRYSTALLINE
1389	GRISEOFULVIN, ULTRAMICROCRYSTALLINE
1391	GUAIFENESIN
1395	GUAIFENESIN; HYDROCODONE BITARTRATE
1402	GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
1403	GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE
1404	GUAIFENESIN; PHENYLPROPANOLAMINE HYDROCHLORIDE
1405	GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
1406	GUAIFENESIN; PSEUDOEPHEDRINE; THEOPHYLLINE
1407	GUAIFENESIN; THEOPHYLLINE
1408	GUANABENZ ACETATE
1410	GUANETHIDINE MONOSULFATE
1412	GUANFACINE HYDROCHLORIDE
1418	HALOPERIDOL
1419	HALOPERIDOL DECANOATE
1427	HEPARIN LOCK FLUSH
1436	HEXACHLOROPHENE
1440	HISTAMINE PHOSPHATE
1444	HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
1450	HYDRALAZINE HYDROCHLORIDE
1451	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
1452	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
1456	HYDROCHLOROTHIAZIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1457	HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE
1458	HYDROCHLOROTHIAZIDE; LISINOPRIL
1459	HYDROCHLOROTHIAZIDE; METHYLDOPA
1460	HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
1461	HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
1462	HYDROCHLOROTHIAZIDE; RESERPINE
1463	HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
1464	HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE
1465	HYDROCHLOROTHIAZIDE; TRIAMTERENE
1468	HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE; PYRILAMINE
1469	HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
1470	HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
1476	HYDROCORTISONE
1477	HYDROCORTISONE ACETATE
1480	HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE
1482	HYDROCORTISONE BUTYRATE
1483	HYDROCORTISONE CYPIONATE
1485	HYDROCORTISONE SODIUM SUCCINATE
1486	HYDROCORTISONE VALERATE
1490	HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1496	HYDROFLUMETHIAZIDE
1497	HYDROFLUMETHIAZIDE; RESERPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1500	HYDROMORPHONE HYDROCHLORIDE
1506	HYDROXYCHLOROQUINE SULFATE
1512	HYDROXYUREA
1513	HYDROXYZINE HYDROCHLORIDE
1514	HYDROXYZINE PAMOATE
1516	HYOSCYAMINE SULFATE
1517	HYOSCYAMINE SULFATE; PHENOBARBITAL
1520	IBUPROFEN
1525	IMIPRAMINE HYDROCHLORIDE
1526	IMIPRAMINE PAMOATE
1529	INDAPAMIDE
1532	INDOMETHACIN
1546	INTERFERON ALFA-2B, RECOMBINANT
1555	IODINATED GLYCEROL
1556	IODINATED GLYCEROL; THEOPHYLLINE
1557	IODINE
1578	IPRATROPIUM BROMIDE
1581	ISOCARBOXAZID
1583	ISOETHARINE MESYLATE
1585	ISONIAZID
1587	ISONIAZID; RIFAMPIN
1590	ISOPROTERENOL HYDROCHLORIDE
1592	ISOSORBIDE
1593	ISOSORBIDE DINITRATE
1595	ISOTRETINOIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1596	ISOXSUPRINE HYDROCHLORIDE
1605	KETOCONAZOLE
1606	KETOPROFEN
1607	KETOROLAC TROMETHAMINE
1612	LEVOTHYROXINE SODIUM
1613	LABETALOL HYDROCHLORIDE
1621	LACTULOSE
1630	LEUCOVORIN CALCIUM
1631	LEUPROLIDE ACETATE
1632	LEVAMISOLE HYDROCHLORIDE
1633	LEVOBUNOLOL HYDROCHLORIDE
1634	LEVOCARNITINE
1635	LEVODOPA
1638	LIDOCAINE
1639	LIDOCAINE HYDROCHLORIDE
1641	LINCOMYCIN HYDROCHLORIDE
1642	LINDANE
1645	LIOTHYRONINE SODIUM
1646	LIOTRIX (T4,T3)
1647	LISINOPRIL
1648	LITHIUM CARBONATE
1660	LOMUSTINE
1661	LOPERAMIDE HYDROCHLORIDE
1662	LORAZEPAM
1664	LOVASTATIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1666	LOXAPINE SUCCINATE
1677	MAGALDRATE; SIMETHICONE
1695	MANGANESE
1705	MEBENDAZOLE
1708	MECLIZINE HYDROCHLORIDE
1710	MECLOFENAMATE SODIUM
1712	MEDROXYPROGESTERONE ACETATE
1713	MEDRYSONE
1714	MEFENAMIC ACID
1716	MEGESTROL ACETATE
1726	MEPENZOLATE BROMIDE
1727	MEPERIDINE HYDROCHLORIDE
1728	MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
1731	MEPHOBARBITAL
1734	MEPROBAMATE
1737	MERCAPTOPYRINE
1742	MESALAMINE
1744	MESORIDAZINE BESYLATE
1747	METAPROTERENOL SULFATE
1749	METAXALONE
1753	METHADONE HYDROCHLORIDE
1759	METHAZOLAMIDE
1761	METHENAMINE HIPPURATE
1762	METHENAMINE MANDELATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1765	METHIMAZOLE
1767	METHIONINE; SODIUM PROPIONATE; UREA
1768	METHOCARBAMOL
1770	METHOTREXATE SODIUM
1777	METHSUXIMIDE
1778	METHYCLOTHIAZIDE
1780	METHYCLOTHIAZIDE; RESERPINE
1787	METHYLDOPA
1789	METHYLERGONOVINE MALEATE
1790	METHYLPHENIDATE HYDROCHLORIDE
1791	METHYLPREDNISOLONE
1795	METHYLTESTOSTERONE
1798	METOCLOPRAMIDE HYDROCHLORIDE
1800	METOLAZONE
1801	METOPROLOL TARTRATE
1803	METRONIDAZOLE
1806	MEXILETINE HYDROCHLORIDE
1809	MICONAZOLE NITRATE
1818	MINOCYCLINE HYDROCHLORIDE
1819	MINOXIDIL
1820	MISOPROSTOL
1826	MOLINDONE HYDROCHLORIDE
1828	MOMETASONE FUROATE
1833	MORPHINE SULFATE
1843	MUPIROCIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1849	NADOLOL
1856	NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
1858	NANDROLONE DECANOATE
1860	NAPHAZOLINE HYDROCHLORIDE
1861	NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE
1864	NAPROXEN
1865	NAPROXEN SODIUM
1868	NEOMYCIN SULFATE
1869	NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1870	NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
1876	NIACIN
1882	NICARDIPINE HYDROCHLORIDE
1884	NICOTINE POLACRILEX
1886	NIFEDIPINE
1890	NITROFURANTOIN
1891	NITROFURANTOIN, MACROCRYSTALLINE
1893	NITROGLYCERIN
1894	NIZATIDINE
1900	NORETHINDRONE ACETATE
1901	NORFLOXACIN
1903	NORTRIPTYLINE HYDROCHLORIDE
1907	NYLIDRIN HYDROCHLORIDE
1908	NYSTATIN
1909	NYSTATIN; TRIAMCINOLONE ACETONIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1916	OMEPRAZOLE
1920	ORPHENADRINE CITRATE
1923	OXACILLIN SODIUM
1926	OXAZEPAM
1927	OXICONAZOLE NITRATE
1929	OXTRIPHYLLINE
1930	OXYBUTYNIN CHLORIDE
1932	OXYCODONE HYDROCHLORIDE
1948	PANCREATIN
1949	PANCRELIPASE
1953	PAPAVERINE HYDROCHLORIDE
1960	PAREGORIC
1963	PEMOLINE
1964	PENBUTOLOL SULFATE
1965	PENICILLAMINE
1968	PENICILLIN G POTASSIUM
1971	PENICILLIN V POTASSIUM
1972	PENTAERYTHRITOL TETRANITRATE
1977	PENTAZOCINE LACTATE
1980	PENTOXIFYLLINE
1986	PERGOLIDE MESYLATE
1988	PERPHENAZINE
1995	PHENAZOPYRIDINE HYDROCHLORIDE
1996	PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE
1998	PHENDIMETRAZINE TARTRATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1999	PHENELZINE SULFATE
2002	PHENIRAMINE; PHENYLPROPANOLAMINE; PYRILAMINE
2003	PHENIRAMINE; PHENYLTOLOXAMINE; PYRILAMINE
2005	PHENOBARBITAL
2013	PHENOXYBENZAMINE HYDROCHLORIDE
2016	PENTERMINE HYDROCHLORIDE
2019	PHENYLBUTAZONE
2020	PHENYLEPHRINE HYDROCHLORIDE
2021	PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
2027	PHENYLPROPANOLAMINE HYDROCHLORIDE
2029	PHENYTOIN
2030	PHENYTOIN SODIUM
2035	PHYTONADIONE
2036	PILOCARPINE HYDROCHLORIDE
2038	PIMOZIDE
2039	PINDOLOL
2046	PIRBUTEROL ACETATE
2047	PIROXICAM
2069	POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE
2070	POLYTHIAZIDE; RESERPINE
2073	POTASSIUM
2078	POTASSIUM BICARBONATE
2081	POTASSIUM CHLORIDE
2084	POTASSIUM GLUCONATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2085	POTASSIUM IODIDE
2086	POTASSIUM IODIDE; THEOPHYLLINE ANHYDROUS
2098	PRAZEPAM
2100	PRAZOSIN HYDROCHLORIDE
2102	PREDNISOLONE
2103	PREDNISOLONE ACETATE
2104	PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
2105	PREDNISOLONE SODIUM PHOSPHATE
2106	PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM
2109	PREDNISON
2114	PRIMIDONE
2115	PROBENECID
2116	PROBUCOL
2117	PROCAINAMIDE HYDROCHLORIDE
2118	PROCAINE HYDROCHLORIDE
2120	PROCHLORPERAZINE
2122	PROGESTERONE
2125	PROMETHAZINE HYDROCHLORIDE
2127	PROPAFENONE HYDROCHLORIDE
2128	PROPANTHELINE BROMIDE
2133	PROPOXYPHENE HYDROCHLORIDE
2134	PROPOXYPHENE NAPSYLATE
2135	PROPRANOLOL HYDROCHLORIDE
2138	PROPYLTHIOURACIL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2143	PROTRIPTYLINE HYDROCHLORIDE
2144	PSEUDOEPHEDRINE HYDROCHLORIDE
2145	PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
2150	PYRAZINAMIDE
2151	PYRIDOSTIGMINE BROMIDE
2152	PYRIDOXINE HYDROCHLORIDE
2156	PYRIMETHAMINE; SULFADOXINE
2160	QUAZEPAM
2162	QUINESTROL
2165	QUINIDINE GLUCONATE
2166	QUINIDINE POLYGALACTURONATE
2167	QUINIDINE SULFATE
2168	QUININE SULFATE
2174	RANITIDINE HYDROCHLORIDE
2176	RAUWOLFIA SERPENTINA
2179	RESERPINE
2188	RIFAMPIN
2203	SALICYLIC ACID
2206	SALSALATE
2218	SELEGILINE HYDROCHLORIDE
2220	SELENIUM SULFIDE
2241	SODIUM BICARBONATE
2243	SODIUM CHLORIDE
2244	SODIUM FLUORIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2258	SODIUM POLYSTYRENE SULFONATE
2260	SODIUM SULFACETAMIDE; SULFUR
2265	SOMATREM
2267	SORBITOL
2269	SPIRONOLACTONE
2270	STANNOUS FLUORIDE
2271	STANOZOLOL
2280	SUCRALFATE
2282	SULCONAZOLE NITRATE
2283	SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE
2284	SULFACETAMIDE SODIUM
2287	SULFAMETHIZOLE
2288	SULFAMETHOXAZOLE
2289	SULFAMETHOXAZOLE; TRIMETHOPRIM
2291	SULFAPYRIDINE
2292	SULFASALAZINE
2293	SULFINPYRAZONE
2294	SULFISOXAZOLE
2298	SULINDAC
2306	TAMOXIFEN CITRATE
2310	TEMAZEPAM
2311	TERAZOSIN HYDROCHLORIDE
2312	TERBUTALINE SULFATE
2313	TERCONAZOLE
2314	TERFENADINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2318	TESTOSTERONE
2319	TESTOSTERONE CYPIONATE
2326	TETRACYCLINE HYDROCHLORIDE
2329	THEOPHYLLINE
2341	THIORIDAZINE HYDROCHLORIDE
2343	THIOTHIXENE
2348	THYROGLOBULIN
2349	THYROID
2353	TIMOLOL MALEATE
2355	TOBRAMYCIN
2357	TOCAINIDE HYDROCHLORIDE
2358	TOLAZAMIDE
2360	TOLBUTAMIDE
2361	TOLMETIN SODIUM
2366	TRANLYCYPROMINE SULFATE
2367	TRAZODONE HYDROCHLORIDE
2368	TRETINOIN
2370	TRIAMCINOLONE
2371	TRIAMCINOLONE ACETONIDE
2374	TRIAMTERENE
2375	TRIAZOLAM
2376	TRICHLORMETHIAZIDE
2381	TRIETHANOLAMINE POLYPEPTIDE OLEATE CONDENSATE
2382	TRIFLUOPERAZINE HYDROCHLORIDE
2385	TRIHEXYPHENIDYL HYDROCHLORIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2390	TRIMETHOBENZAMIDE HYDROCHLORIDE
2391	TRIMETHOPRIM
2394	TRIPLENNAMINE HYDROCHLORIDE
2396	TRIPROLIDINE HYDROCHLORIDE
2400	TROPICAMIDE
2418	URSODIOL
2419	VALPROIC ACID
2425	VERAPAMIL HYDROCHLORIDE
2444	WARFARIN SODIUM
2450	YOHIMBINE HYDROCHLORIDE
2451	ZIDOVUDINE
3004	CALCIUM ACETATE
3007	DOXAZOSIN MESYLATE
3009	ESTAZOLAM
3012	HALOBETASOL PROPIONATE
3014	ISRADIPINE
3015	LEVONORGESTREL
3016	OFLOXACIN
3017	OLSALAZINE SODIUM
3022	METIPRANOLOL HYDROCHLORIDE
3024	PEGADEMASE BOVINE
3029	ETODOLAC
3031	ONDANSETRON HYDROCHLORIDE
3032	RAMIPRIL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
3037	HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
3046	FILGRASTIM
3052	FOSINOPRIL SODIUM
3053	BENAZEPRIL HYDROCHLORIDE
3059	FELODIPINE
3060	DIDANOSINE
3062	PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE
3063	TICLOPIDINE HYDROCHLORIDE
3064	PRAVASTATIN SODIUM
3066	AZITHROMYCIN DIHYDRATE
3068	CLARITHROMYCIN
3069	QUINAPRIL HYDROCHLORIDE
3072	AMLODIPINE BESYLATE
3076	ZALCITABINE
3078	FINASTERIDE
3084	NEDOCROMIL SODIUM
3087	SERTRALINE HYDROCHLORIDE
3088	SIMVASTATIN
3089	SOTALOL HYDROCHLORIDE
3090	SUMATRIPTAN SUCCINATE
3091	TACRINE HYDROCHLORIDE
3102	CEFPROZIL
3106	ISOSORBIDE MONONITRATE
3107	LORACARBEF

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
3108	NABUMETONE
3109	NICOTINE
3110	NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE
3126	CEFPODOXIME PROXETIL
3129	CLINDAMYCIN PHOSPHATE
3130	PAROXETINE HYDROCHLORIDE
3133	ITRACONAZOLE
3140	OXAPROZIN
3143	DESOGESTREL; ETHINYL ESTRADIOL
3145	ZOLPIDEM TARTRATE
3149	TERBINAFINE HYDROCHLORIDE
3156	SALMETEROL XINAFOATE
3161	LORATADINE
3164	CISAPRIDE MONOHYDRATE
3177	FLUOROMETHOLONE ACETATE
3179	TORSEMIDE
3182	RIMANTADINE HYDROCHLORIDE
7000	INSULIN
7500	KAOLIN; PAREGORIC; PECTIN
7501	HYDROCODONE BITARTRATE
7502	TIAPROFENIC ACID
7503	DIPHENOXYLATE HYDROCHLORIDE
0390	BELLADONNA; ERGOTAMINE; PHENOBARBITAL
1503	HYDROQUINONE
3184	LODOXAMIDE TROMETHAMINE

Appendix 2

CODE	DRUG CLASS DESCRIPTION
0100	ANESTHETICS
0117	ANESTHETICS, LOCAL
0118	ANESTHETICS, GENERAL
0119	ANESTHESIA, ADJUNCTS TO/ANALEPTICS
0120	MEDICINAL GASES
0121	ANESTHETICS, TOPICAL
0122	ANESTHETICS, OPHTHALMIC
0123	ANESTHETICS, RECTAL
0200	ANTIDOTES
0281	ANTIDOTES, SPECIFIC
0283	ANTIDOTES, GENERAL
0285	ANTITOXINS/ANTIVENINS
0286	ANAPHYLAXIS TREATMENT KIT
0300	ANTIMICROBIALS
0346	PENICILLINS
0347	CEPHALOSPORINS
0348	LINCOSAMIDES/MACROLIDES
0349	POLYMYXINS
0350	TETRACYCLINE
0351	CHLORAMPHENICOL/DERIVATIVES
0352	AMINOGLYCOSIDES
0353	SULFONAMIDES/RELATED COMPOUNDS
0354	ANTISEPTICS, URINARY TRACT
0355	ANTIBACTERIALS, MISCELLANEOUS
0356	ANTIMYCOBACTERIALS (INCL ANTI LEPROSY)
0357	QUINOLONES/DERIVATIVES
0358	ANTIFUNGALS
0388	ANTIVIRALS
0400	HEMATOLOGICS
0408	DEFICIENCY ANEMIAS
0409	ANTICOAGULANTS/THROMBOLYTICS
0410	BLOOD COMPONENTS/SUBSTITUTES
0411	HEMOSTATICS
0500	CARDIOVASCULAR-RENAL
0501	CARDIAC GLYCOSIDES
0502	ANTIARRHYTHMICS
0503	ANTIANGINALS
0504	VASCULAR DISORDERS, CEREBRAL/PERIPHERAL
0505	HYPOTENSION/SHOCK
0506	ANTIHYPERTENSIVES
0507	DIURETICS
0508	CORONARY VASODILATORS
0509	RELAXANTS/STIMULANTS, URINARY TRACT
0510	CALCIUM CHANNEL BLOCKERS
0511	CARBONIC ANHYDRASE INHIBITORS
0512	BETA BLOCKERS
0513	ALPHA AGONISTS/ALPHA BLOCKERS
0514	ACE INHIBITORS
0600	CENTRAL NERVOUS SYSTEM

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
0626	SEDATIVES/HYPNOTICS
0627	ANTIANKXIETY
0628	ANTIPSYCHOTICS/ANTIMANICS
0630	ANTIDEPRESSANTS
0631	ANOREXIANTS/CNS STIMULANTS
0632	CNS, MISCELLANEOUS
0633	ALZHEIMER-TYPE DEMENTIA
0634	SLEEP AID PRODUCTS, PRIMARY OTC
0635	ANTIEMETICS
0700	CONTRAST MEDIA/ RADIOPHARMACEUTICALS
0789	DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
0790	DIAGNOSTICS RADIOPHARMACEUTICALS
0791	THERAPEUTICS RADIOPHARMACEUTICALS
0792	DIAGNOSTICS-MISC.
0800	GASTROINTESTINALS
0874	DISORDERS, ACID/PEPTIC
0875	ANTIDIARRHEALS
0876	LAXATIVES
0877	GASTROINTESTINAL, MISCELLANEOUS
0878	ANTISPASMODICS/ANTICHOLINERGICS
0879	ANTACIDS
0900	METABOLICS/NUTRIENTS
0912	HYPERLIPIDEMIA
0913	VITAMINS/MINERALS
0914	NUTRITION, ENTERAL/PARENTERAL
0915	REPL/REGS OF ELECTROLYTES/WATER BALANCE
0916	CALCIUM METABOLISM
0917	HEMATOPOIETICS
1000	HORMONES/HORMONAL MECHANISMS
1032	ADRENAL CORTICOSTEROIDS
1033	ADROGENS/ANABOLIC STEROIDS
1034	ESTROGENS/PROGESTINS
1035	ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION
1036	BLOOD GLUCOSE REGULATORS
1037	THYROID/ANTITHYROID
1038	ANTIDIURETICS
1039	RELAXANTS/STIMULANTS, UTERINE
1040	CONTRACEPTIVES
1041	INFERTILITY
1042	DISORDERS OF GROWTH HORMONE SECRETION
1100	IMMUNOLOGICS
1180	VACCINES/ANTISERA
1181	IMMUNOMODULATORS
1182	ALLERGENIC EXTRACTS
1183	IMMUNE SERUMS (INCLUDES IMMUNE GLOBULINS)
1200	SKIN/MUCOUS MEMBRANES
1264	ANTISEPTICS/DISINFECTANTS
1265	DERMATOLOGICS
1266	KERATOLYTICS

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1267	ANTIPERSPIRANTS
1268	TOPICAL STEROIDS
1269	BURN/SUNBURN, SUNSCREEN
1270	ACNE PRODUCTS
1271	TOPICAL ANTI-INFECTIVES
1272	ANORECTAL PRODUCTS
1273	PERSONAL CARE PRODUCTS
1274	DERMATITIS/ANTIPURETICS
1275	TOPICAL ANALGESICS
1300	NEUROLOGICS
1371	EXTRAPYRAMIDAL MOVEMENT DISORDERS
1372	MYASTHENIA GRAVIS
1373	SKELETAL MUSCLE HYPERACTIVITY
1374	ANTICONVULSANTS
1400	ONCOLYTICS
1479	ANTINEOPLASTICS
1480	ANTINEOPLASTICS-HORMONAL/BIOLOGICAL RESPONSE
1481	ANTINEOPLASTICS-ANTIMETABOLITES
1482	ANTINEOPLASTIC AGENTS
1483	ANTINEOPLASTICS-DNA DAMAGING AGENTS
1500	OPHTHALMICS
1566	GLAUCOMA
1567	CYCOPLEGICS/MYDRIATICS
1568	OCULAR ANTI-INFECTIVE/ANTI-INFLAMMATORY
1569	OPHTHALMICS, MISCELLANEOUS
1570	OPHTHALMICS-DECONGESTANTS/ANTI-ALLERGY AGENTS
1571	CONTACT LENS PRODUCTS
1600	OTICS
1670	OTICS, TOPICAL
1671	VERTIGO/MOTION SICKNESS/VOMITING
1700	RELIEF OF PAIN
1720	ANALGESICS, GENERAL
1721	ANALGESICS, NARCOTIC
1722	ANALGESICS, NON-NARCOTIC
1723	ANTIMIGRAINE/OTHER HEADACHES
1724	ANTIARTHRITICS
1725	ANTIGOUT
1726	CENTRAL PAIN SYNDROMES
1727	NSAID-NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
1728	ANTIPYRETICS
1729	MENSTRUAL PRODUCTS
1800	ANTIPARASITICS
1860	ANTIPROTOZOALS
1862	ANTHELMINTICS
1863	SCABICIDES/PEDICULICIDES
1864	ANTIMALARIALS
1900	RESPIRATORY TRACT
1940	ANTIASTHMATICS/BRONCODILATORS
1941	NASAL DECONGESTANTS

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1943	ANTITUSSIVES/EXPECTORANTS/MUCOLYTICS
1944	ANTIHIAMINES
1945	COLD REMEDIES
1946	LOZENGE PRODUCTS
1947	CORTICOSTEROIDS-INHALATION/NASAL
2000	OTHER
2087	QUESTION OF USE
2095	PHARMACEUTICAL AIDS
2096	SURGICAL AIDS
2097	DENTAL PREPARATIONS
2098	DENTRIFICE/DENTURE PRODUCTS
2099	MOUTH PAIN, COLD SORE, CANKER SORE PRODUCTS
2100	HOMEOPATHIC PRODUCTS
9900	NO CLASS ASSIGNED
9998	MULTIPLE USES OF DRUG

Appendix 3

ICD-9-CM

Code Description

```

=====
V01.1    Contact with or exposure to tuberculosis
V07.31   Prophylactic fluoride administration
V07.4    Postmenopausal hormone replacement therapy
V07.9    Unspecified prophylactic measure
V13.3    Personal history of diseases of skin and subcutaneous tissue
V15.0    Personal history of allergy, other than medicinal agents
V15.2    Personal history of surgery to other major organs
V15.82   Personal history of tobacco use
V22.2    Pregnant state, unspecified
V25.2    Encounter for sterilization
V25.9    Encounter for unspecified contraceptive management
V26.2    Procreative management, investigation and testing
V26.9    Unspecified procreative management
V40.3    Other behavioral problems
V40.9    Unspecified mental or behavioral problem
V41.6    Problems with swallowing and mastication
V42.0    Kidney transplant
V42.4    Bone transplant
V42.6    Lung transplant
V42.9    Unspecified organ or tissue transplant
V44.3    Colostomy
V45.6    Postsurgical states following surgery of eye and adnexa
V49.5    Other problems of limbs
V53.6    Fitting and adjustment of urinary devices
V58.1    Encounter or admission for chemotherapy
V58.9    Encounter for unspecified aftercare
V69.9    Problem related to lifestyle, unspecified
V74.1    Special screening examination for pulmonary tuberculosis
003.9    Salmonella infection, unspecified
005.9    Food poisoning, unspecified
008.8    Intestinal infections due to other organisms, not elsewhere
          classified
009.0    Infectious colitis, enteritis, and gastroenteritis
009.1    Colitis, enteritis, and gastroenteritis of presumed infectious
          origin
011.9    Pulmonary tuberculosis, unspecified
017.0    Tuberculosis of the skin and subcutaneous cellular tissue
033.9    Whooping cough, unspecified organism
034.0    Streptococcal sore throat
034.1    Scarlet fever
038.9    Unspecified septicemia
041.0    Streptococcus infection in conditions classified elsewhere and of
          unspecified site
041.1    Staphylococcus infection in conditions classified elsewhere and of
          unspecified site
041.9    Bacterial infection, unspecified
042      Human immunodeficiency virus [HIV] disease
049.9    Unspecified non-arthropod-borne viral diseases of central nervous
          system
052.9    Varicella without mention of complication
053.9    Herpes zoster without mention of complication

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
054.1 Genital herpes
  054.2 Herpetic gingivostomatitis
  054.9 Herpes simplex without mention of complication
  075 Infectious mononucleosis
  078.1 Viral warts
  079.9 Unspecified viral and chlamydial infections
  079.99 Unspecified viral infection
  084.6 Malaria, unspecified
  088.81 Lyme disease
  098.0 Acute gonococcal infections of the lower genitourinary tract
  099.9 Venereal disease, unspecified
  110.0 Dermatophytosis of scalp and beard
  110.1 Dermatophytosis of nail
  110.2 Dermatophytosis of hand
  110.3 Dermatophytosis of groin and perianal area
  110.4 Dermatophytosis of foot
  110.9 Dermatophytosis of unspecified site
  111.0 Pityriasis versicolor
  111.9 Dermatomycosis, unspecified
  112.0 Candidiasis of mouth
  112.1 Candidiasis of vulva and vagina
  112.9 Candidiasis of unspecified site
  117.9 Other and unspecified mycoses
  126.9 Ancylostomiasis and necatoriasis, unspecified
  127.4 Enterobiasis
  128.9 Helminth infection, unspecified
  133.0 Scabies
  135 Sarcoidosis
  136.9 Unspecified infectious and parasitic diseases
  149.0 Malignant neoplasm of pharynx, unspecified
  153.3 Malignant neoplasm of sigmoid colon
  173.4 Malignant neoplasm of scalp and skin of neck
  173.9 Malignant neoplasm of skin, site unspecified
  174.9 Malignant neoplasm of female breast, unspecified
  185 Malignant neoplasm of prostate
  189.0 Malignant neoplasm of kidney, except pelvis
  193 Malignant neoplasm of thyroid gland
  199.1 Other malignant neoplasm, unspecified site (primary) (secondary)
  208.9 Unspecified leukemia
  238.2 Neoplasm of uncertain behavior of skin
  239.6 Neoplasms of unspecified nature of brain
  239.9 Neoplasms of unspecified nature, site unspecified
  240.9 Goiter, unspecified
  242.0 Toxic diffuse goiter
  242.9 Thyrotoxicosis without mention of goiter or other cause
  244.9 Unspecified hypothyroidism
  246.9 Unspecified disorder of thyroid
  250.0 Diabetes mellitus without mention of complication
  250.9 Diabetes with unspecified complication
  251.9 Unspecified disorder of pancreatic internal secretion
  253.9 Unspecified disorders of pituitary gland

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
255.4 Corticoadrenal insufficiency
  256.3 Other ovarian failure
  256.9 Unspecified ovarian dysfunction
  259.9 Unspecified endocrine disorder
  269.0 Vitamin K deficiency
  269.2 Unspecified vitamin deficiency
  269.9 Unspecified nutritional deficiency
  272.0 Pure hypercholesterolemia
  272.5 Lipoprotein deficiencies
  272.9 Unspecified disorder of lipoid metabolism
  274.0 Gouty arthropathy
  274.9 Gout, unspecified
  275.4 Disorders of calcium metabolism
  275.9 Unspecified disorder of mineral metabolism
  276.1 Hyposmolality and/or hyponatremia
  276.5 Volume depletion
  276.6 Fluid overload
  276.9 Electrolyte and fluid disorders not elsewhere classified
  277.0 Cystic fibrosis
  277.6 Other deficiencies of circulating enzymes
  278.8 Other hyperalimentation
  279.2 Combined immunity deficiency
  279.4 Autoimmune disease, not elsewhere classified
  279.9 Unspecified disorder of immune mechanism
  280.9 Iron deficiency anemia, unspecified
  282.6 Sickle-cell anemia
  285.9 Anemia, unspecified
  286.9 Other and unspecified coagulation defects
  287.5 Thrombocytopenia, unspecified
  289.9 Unspecified diseases of blood and blood-forming organs
  290.0 Senile dementia, uncomplicated
  295.3 Schizophrenia of the paranoid type
  295.9 Unspecified schizophrenia
  296.5 Bipolar affective disorder, depressed
  296.7 Bipolar affective disorder, unspecified
  296.8 Manic-depressive psychosis, other and unspecified
  297.9 Unspecified paranoid state
  298.9 Unspecified psychosis
  300.0 Anxiety states
  300.1 Hysteria
  300.21 Agoraphobia with panic attacks
  300.3 Obsessive-compulsive disorders
  300.9 Unspecified neurotic disorder
  302.71 Psychosexual dysfunction with inhibited sexual desire
  304.9 Unspecified drug dependence
  305.0 Alcohol abuse
  305.1 Tobacco use disorder
  305.9 Other, mixed, or unspecified drug abuse
  306.4 Gastrointestinal malfunction arising from mental factors
  307.23 Gilles de la Tourette's disorder
  307.42 Persistent disorder of initiating or maintaining sleep
  
```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
307.49 Other disorders of sleep of nonorganic origin
  307.5 Other and unspecified disorders of eating
  307.81 Tension headache
  308.0 Acute stress reaction, predominant disturbance of emotions
  308.2 Acute stress reaction, predominant psychomotor disturbance
  308.9 Unspecified acute stress
  311 Depressive disorder, not elsewhere classified
  312.89 Other specified conduct disorder, not elsewhere classified
  312.9 Unspecified disturbance of conduct
  314.0 Attention deficit disorder
  314.9 Unspecified hyperkinetic syndrome
  319 Unspecified mental retardation
  322.9 Meningitis, unspecified
  331.0 Alzheimer's disease
  332.0 Paralysis agitans
  333.99 Other extrapyramidal diseases and abnormal movement disorders
  340 Multiple sclerosis
  344.9 Paralysis, unspecified
  345.9 Epilepsy, unspecified
  346.9 Migraine, unspecified
  347 Cataplexy and narcolepsy
  349.0 Reaction to spinal or lumbar puncture
  349.9 Unspecified disorders of nervous system
  350.1 Trigeminal neuralgia
  351.0 Bell's palsy
  351.9 Facial nerve disorder, unspecified
  354.0 Carpal tunnel syndrome
  355.9 Mononeuritis of unspecified site
  360.0 Purulent endophthalmitis
  360.9 Unspecified disorder of globe
  364.3 Unspecified iridocyclitis
  365.9 Unspecified glaucoma
  366.9 Unspecified cataract
  367.2 Astigmatism
  368.8 Other specified visual disturbances
  368.9 Unspecified visual disturbance
  369.8 Unqualified visual loss, one eye
  369.9 Unspecified visual loss
  371.9 Unspecified corneal disorder
  372.3 Other and unspecified conjunctivitis
  373.9 Unspecified inflammation of eyelid
  373.11 Hordeolum externum
  375.15 Tear film insufficiency, unspecified
  375.9 Unspecified disorder of lacrimal system
  379.9 Unspecified disorder of eye and adnexa
  379.91 Pain in or around eye
  379.93 Redness or discharge of eye
  380.12 Acute swimmers' ear
  380.4 Impacted cerumen
  380.9 Unspecified disorder of external ear
  382.9 Unspecified otitis media
  
```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
386.0  Meniere's disease
  386.12 Vestibular neuronitis
  386.3  Labyrinthitis
  386.9  Unspecified vertiginous syndromes and labyrinthine disorders
  388.3  Tinnitus
  388.7  Otalgia
  388.8  Other disorders of ear
  388.9  Unspecified disorder of ear
  391.9  Acute rheumatic heart disease, unspecified
  401.9  Unspecified essential hypertension
  410.9  Acute myocardial infarction, unspecified site
  413.9  Other and unspecified angina pectoris
  414.0  Coronary atherosclerosis
  416.0  Primary pulmonary hypertension
  423.9  Unspecified disease of pericardium
  424.0  Mitral valve disorders
  427.0  Paroxysmal supraventricular tachycardia
  427.1  Paroxysmal ventricular tachycardia
  427.31 Atrial fibrillation
  427.41 Ventricular fibrillation
  427.69 Other premature beats
  427.9  Cardiac dysrhythmia, unspecified
  428.0  Congestive heart failure
  428.9  Heart failure, unspecified
  429.2  Cardiovascular disease, unspecified
  429.8  Other ill-defined heart diseases
  429.9  Heart disease, unspecified
  435.9  Unspecified transient cerebral ischemia
  436    Acute, but ill-defined, cerebrovascular disease
  437.7  Transient global amnesia
  437.9  Unspecified cerebrovascular disease or lesion
  440.2  Atherosclerosis of native arteries of the extremities
  440.9  Generalized and unspecified atherosclerosis
  443.9  Peripheral vascular disease, unspecified
  444.22 Arterial embolism and thrombosis of arteries of the lower
        extremities
  444.9  Arterial embolism and thrombosis of unspecified artery
  446.5  Giant cell arteritis
  447.9  Unspecified disorders of arteries and arterioles
  451.2  Phlebitis and thrombophlebitis of lower extremities, unspecified
  451.9  Phlebitis and thrombophlebitis of unspecified site
  453.9  Other venous embolism and thrombosis of unspecified site
  455.6  Unspecified hemorrhoids without mention of complication
  458.9  Hypotension, unspecified
  459.0  Hemorrhage, unspecified
  459.9  Unspecified circulatory system disorder
  460    Acute nasopharyngitis common cold
  462    Acute pharyngitis
  463    Acute tonsillitis
  464    Acute laryngitis and tracheitis
  464.4  Croup

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
465.9 Acute upper respiratory infections of unspecified site
  471.9 Unspecified nasal polyp
  473.9 Unspecified sinusitis (chronic)
  474.12 Hypertrophy of adenoids alone
  474.9 Unspecified chronic disease of tonsils and adenoids
  477.0 Allergic rhinitis due to pollen
  477.8 Allergic rhinitis due to other allergen
  477.9 Allergic rhinitis cause unspecified
  478.1 Other diseases of nasal cavity and sinuses
  478.2 Other diseases of pharynx, not elsewhere classified
  478.7 Other diseases of larynx, not elsewhere classified
  478.9 Other and unspecified diseases of upper respiratory tract
  486 Pneumonia, organism unspecified
  487.1 Influenza with other respiratory manifestations
  487.8 Influenza with other manifestations
  490 Bronchitis, not specified as acute or chronic
  491.9 Unspecified chronic bronchitis
  492.8 Other emphysema
  493.9 Asthma, unspecified
  496 Chronic airway obstruction, not elsewhere classified
  501 Asbestosis
  511.9 Unspecified pleural effusion
  514 Pulmonary congestion and hypostasis
  515 Postinflammatory pulmonary fibrosis
  518.89 Other diseases of lung, not elsewhere classified
  519.9 Unspecified disease of respiratory system
  520.7 Teething syndrome
  521.0 Dental caries
  521.9 Unspecified disease of hard tissues of teeth
  522.4 Acute apical periodontitis of pulpal origin
  522.5 Periapical abscess without sinus
  522.9 Other and unspecified diseases of pulp and periapical tissues
  523.1 Chronic gingivitis
  523.9 Unspecified gingival and periodontal disease
  524.6 Temporomandibular joint disorders
  525.1 Loss teeth due to accident/extraction/local periodontal disease
  525.9 Unspecified disorder of the teeth and supporting structures
  526.4 Inflammatory conditions of the jaws
  526.9 Unspecified disease of the jaws
  527.9 Unspecified disease of the salivary glands
  528.2 Oral aphthae
  528.3 Cellulitis and abscess of the oral soft tissues
  528.5 Diseases of lips
  528.9 Other and unspecified diseases of the oral soft tissues
  529.9 Unspecified condition of the tongue
  530.1 Esophagitis
  530.11 Reflux esophagitis
  530.2 Ulcer of esophagus
  530.81 Esophageal reflux
  530.9 Unspecified disorder of esophagus
  
```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
531.9 Gastric ulcer unspecified as acute or chronic, without mention of
      hemorrhage or perforation
532.9 Duodenal ulcer unspecified as acute or chronic, without mention of
      hemorrhage or perforation
533.9 Peptic ulcer, site unspecified, unspecified as acute or chronic,
      without mention of hemorrhage or perforation
534.4 Gastrojejunal ulcer chronic or unspecified with hemorrhage
534.9 Gastrojejunal ulcer unspecified as acute or chronic, without
      mention of hemorrhage or perforation
535.5 Unspecified gastritis and gastroduodenitis
536.8 Dyspepsia and other specified disorders of function of stomach
536.9 Unspecified functional disorder of stomach
537.9 Unspecified disorder of stomach and duodenum
541 Appendicitis, unqualified
553.3 Diaphragmatic hernia
553.9 Hernia of unspecified site
555.9 Regional enteritis unspecified site
556.9 Ulcerative colitis, unspecified
558.9 Other and unspecified noninfectious gastroenteritis and colitis
562.0 Diverticula of small intestine
562.00 Diverticulosis of small intestine (without mention of hemorrhage)
562.01 Diverticulitis of small intestine (without mention of hemorrhage)
564.0 Constipation
564.1 Irritable colon
564.6 Anal spasm
787.03 Vomiting alone
787.1 Heartburn
787.2 Dysphagia
787.3 Flatulence, eructation, and gas pain
787.7 Abnormal feces
787.9 Other symptoms involving digestive system
788.0 Renal colic
788.2 Retention of urine
788.3 Incontinence of urine
788.39 Other urinary incontinence
788.41 Urinary frequency
788.69 Other abnormality of urination
788.9 Other symptoms involving urinary system
789.0 Abdominal pain
790.6 Other abnormal blood chemistry
790.9 Other nonspecific findings on examination of blood
791.9 Other nonspecific findings on examination of urine
795.5 Nonspecific reaction to tuberculin skin test without
      active tuberculosis
799.2 Nervousness
799.8 Other ill-defined conditions, causes of morbidity and mortality
799.9 Other unknown and unspecified cause of morbidity and mortality
803.0 Other and unqualified skull fractures closed without mention of
      intracranial injury
805.8 Unspecified fracture of vertebral column without mention of spinal
      cord injury, closed
  
```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
807.0 Fracture of rib(s), closed
814.0 Fracture of carpal bone(s), closed
816.0 Fracture of one or more phalanges of hand, closed
818.0 Ill-defined closed fractures of upper limb
820.8 Fracture of unspecified part of neck of femur, closed
826.0 Closed fracture of one or more phalanges of foot
827.0 Closed other, multiple, and ill-defined fractures of lower limb
839.8 Multiple and ill-defined dislocations, closed
840.4 Sprains and strains of rotator cuff (capsule)
840.9 Sprains and strains of unspecified site of shoulder and upper arm
842.0 Sprains and strains of wrist
844.9 Sprains and strains of unspecified site of knee and leg
845.0 Sprains and strains of ankle
845.1 Sprains and strains of foot
847.0 Sprains and strains of neck
847.2 Sprains and strains of lumbar back
847.9 Sprains and strains of unspecified site of back
848.3 Sprains and strains of ribs
848.9 Unspecified site of sprain and strain
873.4 Open wound of face, without mention of complication
879.8 Open wound(s) (multiple) of unspecified site(s) without mention of
complication
879.9 Open wound(s) (multiple) of unspecified site(s), complicated
892.0 Open wound of foot except toe(s) alone without mention of
complication
894.0 Multiple and unspecified open wound of lower limb without mention
of complication
910.2 Blister of face, neck, and scalp without mention of infection
915.8 Other and unspecified superficial injury of fingers without mention
of infection
915.9 Other and unspecified superficial injury of fingers, infected
916.2 Blister of hip, thigh, leg, and ankle w/o mention of infection
917.8 Other and unspecified superficial injury of foot/toes w/o mention
of infection
918.1 Superficial injury of cornea
918.9 Other and unspecified superficial injuries of eye
919.4 Insect bite of other/multiple/unspecified site, nonvenomous, w/o
mention of infection
919.5 Insect bite of other/multiple/unspecified site, nonvenomous,
infected
919.8 Other and unspecified superficial injury without mention of
infection
923.0 Contusion of shoulder and upper arm
923.9 Contusion of unspecified part of upper limb
924.5 Contusion of unspecified part of lower limb
930.9 Foreign body on unspecified site of external eye
933.1 Foreign body in larynx
944.2 Burn of wrist(s) and hand(s) [second degree], blisters, epidermal
loss
957.9 Injury to nerves, unspecified site
959.0 Face and neck injury, other and unspecified

```

Appendix 3 continued

ICD-9-CM

Code Description

```
=====
959.1 Trunk injury, other and unspecified
959.3 Elbow, forearm, and wrist injury, other and unspecified
959.4 Hand injury, other and unspecified, except finger
959.5 Finger injury, other and unspecified
959.6 Hip and thigh injury, other and unspecified
959.7 Knee, leg, ankle, and foot injury, other and unspecified
959.8 Injury to other specified sites, including multiple
959.9 Injury to unspecified site
984.9 Toxic effect of unspecified lead compound
989.5 Toxic effect of venom
994.6 Motion sickness
995.2 Unspecified adverse effect of drug, medicinal and biological
      substance (due) to correct medicinal substance properly
      administered
995.3 Allergy, unspecified
995.69 Anaphylactic shock due to other specified food
996.8 Complications of transplanted organ
997.6 Late amputation stump complication, not elsewhere classified
999.3 Other infection following medical care, not elsewhere classified
888888 Blank but applicable
999999 Sample person did not know symptom or condition
```

Appendix 4

HAX13A Antacid identification codes

100 ALKA-MINTS CHEWABLE
110 ALKA SELTZER ADVANCED FORMULA/NON-ASPIRIN
111 ALKA SELTZER EFFERVESCENT
112 ALKA SELTZER EFFERVESCENT/PAIN RELIEVER
113 ALKA SELTZER EFFERVESCENT/PAIN RELIEVER-EXTRA STRENGTH
119 ALKA SELTZER - TYPE NOT SPECIFIED
120 ALTERNAGEL LIQUID
139 ALUMINUM ANTACID - TYPE NOT SPECIFIED
149 AMPHOJEL - TYPE NOT SPECIFIED
152 BASALJEL SUSPENSION
159 BASALJEL - TYPE NOT SPECIFIED
169 BISMUTH SUBSALICYLATE PRODUCT - TYPE NOT SPECIFIED
170 BISODOL CHEWABLE TABLETS
171 BISODOL POWDER
180 BROMO SELTZER
199 CALCIUM ANTACID - TYPE NOT SPECIFIED
200 CAMALOX SUSPENSION
201 CAMALOX TABLETS
219 CHARCOAL PRODUCT - TYPE NOT SPECIFIED
220 CHOOZ CHEWABLE TABLETS
230 DI-GEL ADVANCED FORMULA TABLETS
231 DI-GEL ANTIACID/ANTIGAS LIQUID
239 DI-GEL - TYPE NOT SPECIFIED
240 FOAMICON CHEWABLE TABLETS
251 GAS-X TABLETS
260 GAVISCON-2 TABLETS
261 GAVISCON EXTRA STRENGTH RELIEF LIQUID
262 GAVISCON EXTRA STRENGTH RELIEF TABLETS
263 GAVISCON LIQUID
264 GAVISCON TABLETS
269 GAVISCON - TYPE NOT SPECIFIED
281 GELUSIL-II
282 GELUSIL-M
289 GELUSIL - TYPE NOT SPECIFIED
290 KOLANTYL
300 MAALOX EXTRA STRENGTH LIQUID
301 MAALOX EXTRA STRENGTH TABLETS
302 MAALOX NO. 1
303 MAALOX NO. 2
304 MAALOX PLUS EXTRA STRENGTH LIQUID
305 MAALOX PLUS TABLETS
306 MAALOX TC
309 MAALOX - TYPE NOT SPECIFIED
310 MAG-OX 400
320 MILK OF MAGNESIA, PHILLIPS LIQUID
321 MILK OF MAGNESIA, PHILLIPS TABLETS
329 MILK OF MAGNESIA - TYPE NOT SPECIFIED
330 MYLANTA DOUBLE STRENGTH LIQUID
331 MYLANTA DOUBLE STRENGTH TABLETS
332 MYLANTA II LIQUID
333 MYLANTA II TABLETS

Appendix 4 continued

HAX13A Antacid identification codes

334	MYLANTA LIQUID
335	MYLANTA TABLETS
339	MYLANTA - TYPE NOT SPECIFIED
340	MYLICON-125 TABS
341	MYLICON-80 TABS
343	MYLICON TABLETS
349	MYLICON - TYPE NOT SPECIFIED
350	PEPTO BISMOL LIQUID
351	PEPTO BISMOL MAXIMUM STRENGTH LIQUID
352	PEPTO BISMOL TABLETS
359	PEPTO BISMOL - TYPE NOT SPECIFIED
360	PHAZYME-95 TABLETS
364	PHAZYME TABLETS
369	PHAZYME - TYPE NOT SPECIFIED
370	REMEGEL SQUARES
380	RIOPAN ANTIACID CHEW TABLETS
381	RIOPAN ANTIACID SUSPENSION
383	RIOPAN PLUS 2 CHEW TABLETS
384	RIOPAN PLUS 2 SUSPENSION
385	RIOPAN PLUS CHEW TABLETS
386	RIOPAN PLUS SUSPENSION
389	RIOPAN - TYPE NOT SPECIFIED
390	ROLAIDS CALCIUM RICH, SODIUM FREE
391	ROLAIDS EXTRA STRENGTH
399	ROLAIDS - TYPE NOT SPECIFIED
409	SODIUM BICARBONATE (BAKING SODA)
410	TEMPO SOFT ANTACID
420	TITRALAC LIQUID
421	TITRALAC TABLETS
430	TUMS ANTIACID TABLETS
431	TUMS E-X ANTIACID TABLETS
432	TUMS LIQUID EXTRA STRENGTH
433	TUMS LIQUID EXTRA STRENGTH W/SIMETHICONE
439	TUMS - TYPE NOT SPECIFIED
441	WINGEL LIQUID
459	OTHER ANTACIDS
blank	INAPPLICABLE
8-FILL	BLANK BUT APPLICABLE
9-FILL	DON'T KNOW

References:

Denniston PL Jr, Epner JA, eds. Physicians GenRx, 1994: The Official Drug Reference. Smithtown, NY: Data Pharmaceutica Inc. 1993.

Product Information Management Branch. National Drug Code Directory. Vol. II. Rockville, MD: Food and Drug Administration. 1985.